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Thesis Abstract
THE EFFECTS OF AN INFLAMMASOME INHIBITOR OLT1177 ON THE
DEVELOPMENT OF ISCHEMIC HEART FAILURE

By Joseph S. Aliaga, BS
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2020

Background: Evidence suggests that prolonged and enhanced pro-inflammatory signaling,
modulated by the NLRP3 inflammasome, plays a crucial role in the pathophysiology of several
different types of cardiovascular diseases such as acute myocardial infarction (AMI), adverse
ventricular remodeling, and heart failure (HF). Consequently, we hypothesize that attenuating the
enhanced inflammatory response using a pharmacological NLRP3 inflammasome inhibitor
would decrease cell death, improve cardiac function, limit adverse cardiac remodeling, and
overall reduce the risk of developing ischemic heart failure. We investigated the role of the
NLRP3 inflammasome after a nonreperfused AMI, by studying the effects of inhibiting the
NLRP3 inflammasome.

Methods: In this study we used a mouse model of acute myocardial infarction (AMI) due to
permanent coronary artery ligation. We assessed cardiac function in mice using transthoracic
echocardiography 3 days after inducing a large nonreperfused AMI, via permanent ligation of the
LAD coronary artery, and select mice with large nonreperfused anterior infarct (> 4 akinetic
segments involving the anterior wall) as well as an enlarged ventricle (left ventricular end-
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diastolic diameter [LVEDD] > 4.4 mm) and systolic dysfunction (left ventricular ejection
fraction [LVEF] < 40%). The mice were then randomly assigned to one of four groups.
Group 1 (n=8) consisted of mice with an AMI and were fed OLT1177, a NLRP3 inflammasome
inhibitor admixed with the chow in the diet (3.75 gr/kg) for 10 weeks. Group 2 (n=7) consisted
of mice with an AMI and were fed OLT1177, a NLRP3 inflammasome inhibitor admixed with
the chow in the diet (7.5 gr/kg) for 10 weeks. Group 3 (n=7) consisted of mice with AMI that
were fed a standard diet (without OLT1177) for 10 weeks. Group 4 (n=6) consisted of mice that
underwent a sham operation and had no AMI and were fed a standard diet for 10 weeks. We
repeated transthoracic echocardiography assessments 4-weeks and 10-weeks after coronary
artery ligation surgery with an assessment of changes in LVEF, along with isoproterenol
challenge in order to measure contractile reserve, a surrogate for cardiorespiratory fitness. The
surviving mice underwent LV catheterization, a terminal procedure, in order to evaluate left
ventricular diastolic function in vivo by measuring left ventricular end-diastolic pressure.

Results: At the end of 10 weeks, 2 of 10 mice (20%) had died in OLT 3.75 gr/kg group, as
compared with 2 of 9 (22%) in the OLT 7.50 gr/kg group, 3 of 10 mice (30%) in the control diet
group, and 0 of 6 mice (0%) in the sham-operated group. Treatment with OLT 3.75 gr/kg or 7.50
gr/kg led to preservation of contractile reserve (percent increase in LVEF after isoproterenol
challenge [+3311% or +406% vs +97 % in standard diet; P<0.05 and P<0.005 respectively).
Treatment with OLT 3.75 gr/kg or 7.5 gr/kg also led to preservation of diastolic function (left
ventricular end-diastolic pressure 3.20.5 mmHg, or 4.50.5 mmHg vs 10.01.6 mmHg in
standard diet; P<0.005 and P<0.009). These effects were independent of effects on ventricular
remodeling after AMI.

viii

Conclusions/implications: The results presented in this study show that NLRP3 inhibition with
OLT1177 can preserve ß-adrenergic responsiveness and prevent left ventricular diastolic
dysfunction in large nonreperfused anterior AMI thereby reducing the risk of developing postinfarct heart failure.

Keywords: Acute myocardial infarction, cardiac remodeling, heart failure, NLRP3
inflammasome, NLRP3 inflammasome inhibitor, OLT1177
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Thesis Introduction
This thesis document has been organized to include a relevant review of background
information regarding acute myocardial infarction, ventricular remodeling, and heart failure. An
overview is also presented on the physiological processes that follow a myocardial infarction that
occurs in an inflammatory response mediated by the NLRP3 inflammasome. Lastly, this article
provides a brief overview of a novel inflammasome inhibitor (OLT1177) and discusses its
potential use as a pharmacological intervention targeting inflammation in a nonreperfused AMI
murine model study.
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CHAPTER 1: Motivation and Significance
1.1 Background
The American Heart Association approximates that every 40 seconds, an American has a
heart attack (MI). Correspondingly, the number of acute myocardial infarctions is rising, and as a
result has become one of the most prevalent causes of hospitalization and death in the United
States (Benjamin et al., 2019). Even so, thanks to medical advancements, and the continuous
improvement in effective and prompt medical treatment, patients are surviving and living longer
after a myocardial infarction(s). However, just as more people are living longer after an MI, there
has been a continuous rise in the prevalence of post-MI heart failure (Benjamin et al., 2019)
According to current scientific literature, infarcted myocardium in most patients can be
salvaged if coronary arterial flow and patency is restored promptly (Cohen et al., 2010).
Conversely, evidence-based findings show that if treatment is delayed, myocardial infarct size or
rate of myocardial cell death/injury increases resulting in a higher risk of developing a
maladaptive form of cardiac remodeling that is mediated by neurohormonal and inflammatory
signaling pathways. This form of adverse cardiac remodeling is one of many factors that over
time contributes to the risk of developing post-MI heart failure, both for short-term and extended
periods of time (Azevedo et al., 2016). For this reason, therapies developed in the last 20 years,
such as those that target neurohormonal signaling pathways, and current/novel therapies that are
targeting inflammatory signaling pathways are being developed and continually improved upon
with the intent of preventing adverse cardiac remodeling and heart failure (Bhatt et al., 2017).
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1.1.1 Acute Myocardial Infarction (AMI)
Under normal physiological conditions, the heart’s atria and ventricles work in unison to
carry out the hearts main function – pumping blood in a unidirectional manner throughout the
body. This highly coordinated, continuous, and life-long form of perfusion is controlled by the
heart’s conduction system consisting of myogenic (spontaneous contraction initiated by the
heart) electrical impulses that begin at the sinoatrial (SA) node located in the right atrium. This
impulse next spreads throughout the walls of both right and left atria, then to the atrioventricular
(AV) node, AV bundle, and to the rest of the Purkinje muscle fibers in right and left ventricles.
Once these ventricle chambers receive the impulse myocardial cells contract, creating a pressure
that is capable of opening heart valves and pumping blood through the pulmonary artery and to
the lungs for blood oxygenation, as well as through the aorta and arterial circulation; whereby the
body’s muscles and tissues, including the heart’s myocardium via coronary arteries, receives
oxygenated blood and nutrients.
Although the SA node works as the “heart’s natural pacemaker” capable of affecting and
altering heart rate, blood pressure, contractility, and coronary artery flow; there are other factors
that also play a role in regulation. These factors include nerve impulses from the autonomic
nervous system (parasympathetic and sympathetic) and neurohormonal effects regulated by the
sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS).
Together in a dynamic manner, the heart’s conduction system, autonomic nervous system, and
neurohormonal effects help create a balance between the heart’s O2 demand and O2 supply.
An instance when this balance is altered, occurs when a coronary artery is partially or
completely occluded resulting in a decrease of O2 supply to the myocardium (ischemia) that can
eventually lead to an acute myocardial infarction (AMI). Furthermore, the occlusion of a
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coronary artery can swiftly lead to ischemic injury, and the impairment of myocardial
metabolism (decreased cellular ATP levels) resulting in cell swelling and necrotic cell death in
the ischemic area, and apoptosis in the ischemic tissue, the surrounding border zone, and nonischemic myocardial area (Abbate et al., 2002).
A key feature of cell death during an AMI is that it progresses in the left ventricle wall
from the subendocardium toward the myocardium and epicardium in a transmural manner (M.
Tanaka, V. Richard, C. Murry, R. Jennings, Reimer, 1993). The reasons for this cell death
progression are due to the subendocardium being subjected to the highest pressure coming from
the ventricular chamber filled with blood, having fewer collateral blood vessel connections, and
to being perfused by coronary arteries that must first reach and pass through layers of contracting
myocardium (Lilly, 2013). Additionally, cardiac tissue that is directly supplied by an occluded
coronary artery will die quickly, whereas tissue adjacent to the myocardial infarct can survive
temporarily under ischemic conditions, due to collateral vessels from neighboring non-occluded
coronary arteries. Nevertheless, as more time passes under ischemic conditions, tissue adjacent
to the myocardial infarct will unavoidably succumb to infarction/necrotic cell death (Lilly,
2013). Together, the prolongation and severity of ischemia, impairment of myocardial
metabolism, and necrotic cell death will lead to a cascade of events such as acute inflammation
and immune cell recruitment which further increases cell death, inflammatory signaling, and loss
of cardiac function. Additionally, characteristic AMI symptoms do occur in the form of
systolic/diastolic dysfunction, arrhythmia, chest pain, shortness of breath, changes in protein
levels (cTnI, cTnT, and CK-MB) proportional to the amount of cardiac tissue that is damaged,
and the inflammatory responses to the myocardial injury (Pandey et al., 2020).
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1.1.2 Diagnosis of Acute Myocardial Infarction (AMI)
While there exist various subtypes of myocardial infarction related to its causes, the two
most prevalent types are type I and type II AMI. A type I AMI, also known as a spontaneous MI,
refers to a myocardial infarction caused by an atherothrombosis or blood clot forming in the
lumen of a coronary artery and causing a sudden (partial or complete) occlusion which
significantly decreases the flow of blood through the coronary artery. What precedes the
formation of an atherothrombosis is the loss of integrity that occurs at the level of an
atherosclerotic plaque’s protective covering (fibrous cap) resulting in the release of its
thrombogenic and lipid-rich contents into the lumen of a coronary artery following plaque
erosion, plaque rupture, fissuring, or dissection (Lilly, 2013). Following the exposure of the
plaque’s content coming into contact with the blood, the activation of the coagulation cascade,
and the formation of an atherothrombosis follows (Burke et al., 2014). Conversely, a type II
AMI, also known as secondary MI, refers to a myocardial infarction that is not the result of a
primary coronary artery event/atherothrombosis. Examples of the causes that lead to type II
AMIs are the following: coronary artery spasm, coronary embolism, anemia, and hypotension
(Thygesen et al., 2012).
When diagnosing an acute myocardial infarction, clinicians rely on identifying the
following criteria: acute onset of angina (chest pain), symptoms of ischemia along with
electrocardiograms showing new ST-elevation, abnormal Q wave, or new left bundle branch
block (LBBB), and evidence of myocardial necrosis through the use of blood tests to detect a rise
and/or fall of cardiac biomarker values such as cardiac troponin (cTn) and creatine kinase
myocardial band (CK-MB) (Thygesen et al., 2012). The reasoning behind utilizing these
biomarkers is that once cardiac muscle/myocardium is injured, its cardiomyocytes will release
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these biomarkers into the bloodstream at a greater rate. On the other hand, if a cardiac muscle
injury has improved, via reperfusion treatments, these cardiac biomarkers would decrease
(Antman et al., 1996). As a result, the assessment of cardiac biomarkers like cardiac troponin
(cTnI and cTnT) levels in the blood have been implemented and used as a diagnostic indicator of
myocardial damage, and thus useful in diagnosing and managing the type of myocardial
infarction or other various forms of heart muscle damage presently taking place in a
patient(Lilly, 2013). As an added piece of information, the initial rise in troponin levels in the
blood occurs within 2-3 hours after an MI and according to a recent finding, levels may persist
and be elevated for up to 2 weeks after an MI (Aydin et al., 2019)
Another form of assessing or diagnosing an acute myocardial infarction is through
imaging techniques such as transthoracic echocardiography (TTE). As a non-invasive imaging
technique, transthoracic echocardiography (TTE) allows one to detect the following: the number
of segments displaying regional wall abnormalities during a myocardial infarction, the size of an
infarct, the progress of a healing or healed myocardial infarction, as well as adverse ventricular
remodeling resulting from a myocardial infarction. (Abouzaki & Abbate, 2016). An additional
non-invasive imaging technique is the cardiac magnetic resonance imaging (cMRI or CMR). The
application of cMRI with the use of gadolinium enhancement allows clinicians to take more
precise measurements and tissue characterization than TTE, such as being capable of
distinguishing between reversible and irreversible myocardial injury (Abouzaki & Abbate, 2016)
(Fieno et al., 2000). Thus, it is oftentimes labeled as the gold standard in diagnosing and
evaluating the progression of an AMI (Bhatt et al., 2017).
After an assessment of the AMI has been made, the main goal of treatment is to salvage
ischemic cardiomyocytes of the myocardium thereby limiting the progression of ischemic
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necrotic cell death. To accomplish this, focus is placed on timely/prompt reperfusion methods
like the following: antithrombotic drugs to dissolve the thrombus (thrombolytics), and
percutaneous coronary intervention (PCI) that includes the utilization of emergency
catheterization and coronary stents (or drug-eluting stents) to help open or increase the diameter
necessary to restore blood flow in plaque-occluded coronary arteries.
All things considered, the combined utilization of electrocardiograms, cardiac biomarker
tests, and non-invasive imaging techniques, are vitally essential. Thanks to these medical
advancements, clinicians are better able to diagnose AMIs, evaluate infarct size and develop
appropriate and timely reperfusion strategies, that are not only vital in salvaging damaged
myocardial tissue, but also important in preventing adverse cardiac remodeling and post-MI
heart failure, thereby improving survival rates and prognosis of patients who have undergone an
AMI (Bhatt et al., 2017)

1.1.3 Adverse Ventricular Remodeling
Following myocardial ischemia and subsequent acute myocardial infarction, treatment in
the form of reperfusion and pharmacological medications is time-sensitive and will affect the
prognosis of patients undergoing a myocardial infarction. Consequently, patients, who receive
reperfusion treatment past optimal/therapeutic treatment times, will be at higher risk of
developing larger transmural infarcts, adverse ventricular remodeling, wall rupture, and even
heart failure (Abouzaki & Abbate, 2016)
To prevent these detrimental outcomes and to maintain circulatory function, namely
stroke volume (SV) and cardiac output (CO), the heart employs an acute compensatory response
known as ventricular remodeling (Weisman et al., 1985). According to scientific literature, the
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term ventricular remodeling refers to morphologically characteristic changes that include dilation
of the ventricle, disproportionate thinning and dilation of the infarcted region, formation of a
scar, and geometrical changes in the overall LV shape (i.e. ellipsoid to more spherical shape)
(Weisman et al., 1985). These compensatory effects are regulated by the Frank-Starling
mechanism, neurohormonal activation (SNS and RAAS), and the body’s innate immune
inflammatory response.
During the first 3-4 days after an AMI, myocardial cell death, loss of contractility
(systolic dysfunction), and area of necrosis progresses in the LV. In response to myocardial cell
death, an influx of inflammatory cells removes cellular debris and promotes the destruction of
collagen scaffolding that helps maintain ventricular shape. (Cleutjens et al., 1995). Additionally,
it is important to note that the degree of this inflammatory response to myocardial injury varies
according to the size of the infarct and to each individual’s genetic and epigenetic factors that
control inflammation (Stylianou, 2019).
Furthermore, ventricular remodeling can occur with the intent of preserving the heart’s
cardiac output (CO) by way of stretching LV myocardial fibers, resulting in regional thinning
and acute dilatation of viable myocardium in the infarcted areas. Consequently, the dilatation of
the LV myocardium increases the preload/amount of blood returned to the heart (LVEDV) via
the Frank-Starling mechanism. This increase in preload, from LV dilation and stretching of LV
myocardial fibers, creates an increased tension between cardiomyocytes’ filaments (Mann,
2011), that leads to an increase in the force of contraction (inotropic activity) from ß-adrenergic
receptor stimulation, thereby increasing stroke volume and adequately maintaining the heart’s
cardiac output (Westman et al., 2016a).
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Weeks to months following an AMI, progressive ventricular remodeling, LV dilatation
coupled with non-compliant scar formation, increases wall stress in the LV chamber, and causes
myocardium to undergo eccentric hypertrophy (M. Pfeffer E. Braunwald, 1990). This increase in
wall stress, according to the Laplace relationship can lead to further LV dilatation that causes the
heart to become less elliptical and more spherical (Westman et al., 2016b)
Other factors that drive adverse cardiac remodeling are neurohormonal activation
regulated by the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone
system (RAAS). In response to decreased CO, the SNS releases epinephrine and norepinephrine
which affects the heart by increasing, peripheral vascular resistance, HR, SV, BP, and
contractility when ß-adrenergic receptors are stimulated. It is particularly useful in helping the
body and tissues meet increases in O2 demand whether during exercise or even during an AMI.
Conversely, persistent SNS activation by way of catecholamines leads to detrimental effects on
the recovering or post-infarcted heart such as hypertrophy, enhanced apoptotic pathways, and
reduced cardiac function that all promote fibrosis and further damage (Bhatt et al., 2017)
Chronic SNS activation also promotes the renin-angiotensin-aldosterone system (RAAS)
activation. Through the RAAS, the enzyme renin cleaves angiotensinogen to angiotensin I which
is then cleaved by angiotensin-converting enzyme (ACE) to help convert angiotensin I to
angiotensin II. The increased expression of angiotensin II promotes vasoconstriction and has a
direct cytotoxic effect on cardiac myocytes, leading to the acceleration of apoptosis and the
promotion of cell hypertrophy. In addition, studies in animal models have shown that angiotensin
II infusion leads to increases in perivascular and interstitial collagen content (Sigusch et al.,
1996) as well as aldosterone secretion which promotes sodium reabsorption and fluid retention,
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impairment of arterial compliance, increases in total peripheral resistance (TPR), and HTN
(Lilly, 2013).
All things considered, as time passes adverse ventricular remodeling modulated by
inflammation, non-compliant scar formation, and neurohormonal activation can lead to further
LV dysfunction and reduced cardiac output that can result in volume overload and develop into
ischemic heart failure (Lilly, 2013).

1.1.4 Heart Failure
Heart failure (HF) is a disease whose onset can be chronic (compensated heart failure) or
acute (decompensated heart failure). As a clinical syndrome, heart failure is often attributed to
being a final common pathway of many cardiac diseases resulting in a decrease in cardiac output
that causes patients to experience dyspnea, fatigue, poor-exercise intolerance, and volume
overload. In addition, heart failure patients can also display orthopnea, paroxysmal nocturnal
dyspnea (PND), edema, and abdominal distention (ascites). The manner in which a decreased
cardiac output can lead to heart failure symptomatology results from many functional or
structural heart disorders that can impair the ventricles’ systolic and diastolic function. Some of
these disorders, such as coronary artery disease (CAD), hypertension (HTN), dilated
cardiomyopathy (DCM), or an AMI, affects the heart’s ability to pump blood, to the point of no
longer being able to meet the body's metabolic O2 demand. Along those lines, more than 2/3 of
all HF cases can be attributed to 4 underlying conditions: Ischemic heart disease (CAD), chronic
obstructive pulmonary disease (COPD), hypertensive heart disease, and rheumatic heart disease.
(Hawkins et al., 2009).
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There are two types of HF that are categorized based on left ventricular ejection fractions
(LVEF). The first type of heart failure, heart failure with reduced EF (HFrEF), is a form of heart
failure that is directly caused by systolic dysfunction and the ventricle’s diminished capacity to
eject blood. The systolic dysfunction that occurs in HFrEF is characterized by a left ventricular
ejection fraction < 40% along with concurrent HF symptoms. Furthermore, systolic dysfunction
is caused by secondary cardiac issues that alter myocardial cell function, through inflammatory
processes, cell death, and fibrosis. As a result, damage caused by MI is commonly associated
with HFrEF (Gerber et al., 2016). The second type of HF, heart failure with preserved EF (LVEF
> 50%), refers to heart failure symptoms caused by diastolic dysfunction resulting from the
ventricle’s diminished capacity to relax and fill during diastole. Conditions that lead to diastolic
dysfunction include cardiac issues that increase the stiffness of the ventricular wall by way of LV
hypertrophy, or fibrosis. A common sign displayed by HFpEF patients is vascular congestion
due to elevated diastolic pressure in the ventricles being transmitted in a retrograde manner to the
pulmonary and systemic veins (Lilly, 2013). As a whole, the distinction between HFrEF and
HFpEF and their etiologies continues to be vital in guiding therapeutic interventions for the
growing number of HF patients.
According to clinical guidelines, there is no single diagnostic test for HF. Instead,
diagnosing heart failure involves a combination of physician assessments, biomarker studies,
imaging data from non-invasive techniques (TTE, cMRI), or invasive hemodynamic
catheterization (Yancy et al., 2016). After completing these assessments, clinicians are able to
evaluate at-risk and current heart failure patients by way of the American College of Cardiology
Foundation/American Heart Association and New York Heart Association functional
classification systems. The ACCF/AHA stages of HF place emphasis on the development and
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progression of disease, whereas the NYHA classes place emphasis on an individual’s exercise
capacity and their present symptomatic status of the disease (Yancy et al., 2016). By focusing on
different aspects of HF, both classification systems are important in helping to provide
appropriate guideline-directed medical therapy (GDMT).
Currently, GDMT for heart failure is complex and utilizes an array of therapies that can
be pharmacological, interventional, or surgical. The goal of these therapies is to regulate and
keep the once compensatory mechanisms in physiological range, manage symptoms, and prevent
and limit further decline. However, even with current and improved guideline-directed medical
therapies, the absolute mortality rate for patients with HF is approximately 50% within the first
five years of diagnosis (Roger et al., 2012). It appears that once a patient reaches HF, what
follows is a vicious trajectory of morbidity and mortality that involves multiple hospital
readmissions, numerous medications prescribed, and debilitating symptoms that significantly
affects the quality of life. For these reasons, medical research continues to strive to find ways to
not only improve GDMT but also prevent the development of HF, whether through
improvements in diet, activity, and medications.
One way that GDMT seeks to improve upon is in the utilization of pharmacological
therapies to target risk factors such as ischemic heart disease and compensatory mechanisms that
lead to adverse ventricular remodeling and heart failure. Currently neurohormonal
blockade/antagonism is the cornerstone of GDMT for the prevention of adverse ventricular
remodeling in patients with MI (Ponikowski et al., 2016). Seeing that compensatory mechanisms
are regulated by neurohormonal signaling pathways, many types of neurohormonal antagonist
medications have been developed such as ACE inhibitors, angiotensin-receptor blockers (ARB),
ß-blockers, and mineralocorticoid-receptor antagonists.
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Furthermore, due to preclinical (Toldo et al., 2019) and clinical (B. W. Van Tassell et al.,
2017) findings, evidence has been mounting in support of classifying inflammatory responses as
a major contributor in the pathophysiology of MI, adverse cardiac remodeling, and HF (Van
Linthout & Tschöpe, 2017). As a result, there has been a gradual shift in ideology from targeting
solely neurohormonal and atherosclerotic mechanisms, to also targeting and attenuating the
inflammatory processes during the stages that lead up to HF as well as after its onset, with the
goal of improving symptoms and preventing HF progression.
One particular human clinical trial that has spearheaded the shift in ideology to target and
label inflammation as a pathogenic contributor to cardiovascular disease, is the Canakinumab
Anti-inflammatory Thrombosis Outcomes Study (CANTOS). In 2011, this large-scale,
randomized, double-blind, placebo-controlled clinical trial began. In total it consisted of testing
10,061 patients in 39 countries with previous AMI and high levels of CRP (>2mg/L), and at
median follow-up of 3.7 years to see whether an anti-inflammatory drug, canakinumab -- a
monoclonal antibody blocking interleukin-1ß (IL-1ß), could prevent and lower rates of recurrent
cardiovascular events. The results, published in 2017, showed that patients taking canakinumab
(150 mg/3 months) had reduced CRP levels and significantly reduced cardiovascular events
independent of lipid levels, thus providing proof-of-principle that adequate inhibition of the
inflammatory pathway from IL-1ß to IL-6 to CRP can significantly reduce cardiovascular events
(Ridker et al., 2017) (Abbate, 2017).

1.1.5 Inflammation in AMI
Inflammation is mainly an innate immune response that is highly coordinated. Its purpose
is to prevent infection, induce innate and adaptive immune processes, as well as stimulate
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healing at the site of injury or infection through leukocyte chemotaxis. With an etiology that can
be infectious or non-infectious, inflammation can occur in response to various pathogenic factors
like bacteria, viruses, and other microbes, or due to non-infectious triggers and signals resulting
from tissue injuries such as trauma, physical injury, toxins, burns, or cell death (that occurs
following a myocardial infarction) (Chen et al., 2018). Additionally, there are specific organs
that exhibit organ-specific inflammatory responses that are modulated according to an
individual’s immune capabilities as well as to the site of injury or infection. These organs include
the heart, pancreas, liver, kidney, lung, and brain (Chen et al., 2018).
The responsibility of initiating and regulating the acute inflammatory response relies
mostly on innate immunological cells such as neutrophils, tissue macrophages derived from
circulating monocytes, and dendritic cells. In order to destroy and remove pathogens and cell
debris, these innate immunological cells detect molecular signals through the use of germ-lineencoded pattern-recognition receptors (PRRs) (Hirayama et al., 2018). PRRs are capable of
detecting/recognizing microbial structures such as pathogen-associated molecular patterns
(PAMPs) and damage-associated molecular patterns (DAMPs) that can lead to the formation of
cytosolic macromolecular complexes (inflammasomes) and the downstream release of
inflammatory mediators (chemokines and cytokines: IL-1ß, IL-6 TNF-⍺ etc.). The release of proinflammatory mediators from the cell are what lead to increased vascular permeability resulting
in the following: increased recruitment of leukocytes to the site of injury/infection, the release of
inflammatory markers/proteins (e.g. CRP, fibrinogen) from the liver, as well as the clinical signs
of inflammation – pain, fever, redness, edema/swelling, and loss of function (Chertov et al.,
2000)
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Pattern-recognition receptors are subdivided into two major classes based on their
cellular localization (Bedard et al., 2019). The first major class of PRRs is found in the cell
membrane: Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) (Medzhitov, 2010).
The second class of PRRs is cytoplasmic PRRs and they include retinoic acid-inducible gene
(RIG-I-Like) receptors, the AIM2-like receptors (ALRs), and the NOD-like receptors (NLRs)
(Bedard et al., 2019). Among these cytoplasmic PRR sensors NLRs, ALRs and pyrin trigger a
distinct defense mechanism that leads to the assembling of cytosolic macromolecular protein
complexes, known as inflammasomes, which are responsible for utilizing caspase-1 to process
pro-interleukin-1ß (IL-1ß) and pro-IL-18 to their mature forms. Thus, the importance in
understanding the functioning/physiological mechanisms of PRRs is indispensable seeing that
PRRs and inflammasomes are what allow innate immune cells to initiate acute inflammatory
responses thereby acting as the body’s first line of defense against PAMPs and DAMPs in the
extracellular milieu (Martinon et al., 2002).
Much of what we know from the inflammatory response that follows a myocardial
infarction comes from preclinical studies on mice. In Figure 1 we see a descriptive diagram
demonstrating the types of inflammation that follows an AMI. Beginning with the inflammatory
phase in which an intense sterile inflammation leads to immune cells being recruited to serve in
digesting and removing damaged cells (≈0 - 4 d in mice), followed by a reparative and
proliferative phase in which neovascularization occurs along with inflammation being
suppressed and resolved (≈4 -14 days) (Prabhu et al., 2017).
As important as it is for immune cells to initiate an acute inflammatory response, it is also
important for them to have mechanisms in place to resolve inflammation when no longer
necessary. A regulated inflammatory response utilizes a combination of the following
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mechanisms to terminate an inflammatory response: upregulation of anti-inflammatory
cytokines/molecules (such as IL-10), downregulation of pro-inflammatory cytokines, short halflife of inflammatory mediators, and the cessation of tissue infiltration by neutrophils that results
in the initiation of programmed cell death (apoptosis) and subsequent neutrophil clearance by
phagocytosis from macrophages (Freire & Van Dyke, 2013). Furthermore, an inflammatory
response is considered resolved with the departure of macrophages through the lymphatic system
(Ortega-Gómez et al., 2013). In addition to the processes that resolve inflammation during the
reparative phase, scar formation mediated by fibroblasts and myofibroblasts occurs, due to the
heart’s limited capacity to regenerate after injury (≈4 -14 days).
However, in the weeks to months that follow an AMI, if post-infarction inflammation is
not suppressed and continues, then this form of post-infarction chronic inflammation coupled
with overactive fibrosis can lead to additional tissue damage, increasing interleukin-1ß (IL-1ß)
release, maladaptive scar formation, and adverse ventricular remodeling. All of which increase
the risk of developing HF (Prabhu et al., 2017).
As a result, today inflammation as a pathogenic contributor to disease is a focus of
research in many different fields involving diabetes mellitus (Goldfine & Shoelson, 2017), ALS
(Meissner et al., 2010), cardiovascular disease (B. W. Van Tassell et al., 2017), and cancer
research (Mantovani et al., 2008).
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Figure 1: Inflammation post-acute myocardial infarction (Prabhu et al., 2017)

1.2 The NLRP3 Inflammasome
The inflammasome, identified first in 2002 by Dr. Jurg Tschopp and colleagues
(Martinon et al., 2002), is a macromolecular protein complex responsible for sensing danger
signals, activating caspases, and pyroptotic release of pro-inflammatory cytokines initiating
inflammatory signaling pathways (Swanson et al., 2019) (Toldo & Abbate, 2018).
Since Tchopp and colleagues’ groundbreaking work, other studies (Martinon et al., 2006)
have identified and elucidated the regulatory mechanisms, oligomerization components, and
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agonists of different types of inflammasomes named after the pattern-recognition receptor (PRR)
regulating their activity (Lamkanfi & Dixit, 2014). Some of these inflammasomes include the
NRLP1, NLRP3, NLRC4, and AIM2 inflammasomes. More importantly these findings from
these initial studies have helped in detailing the role and delicate balance that inflammasomes
help maintain during an innate immune inflammatory response. In particular when
physiologically regulated, inflammasomes play an integral role in controlling innate immune
pathways responsible for inflammation, host defense, and protection from injury and sepsis
(Dagenais et al., 2012). Conversely, inflammasomes that are over-stimulated or not sufficiently
suppressed can lead to exuberant inflammatory responses that are linked to many different
inflammatory diseases (Dagenais et al., 2012).
Of all the inflammasomes that have been identified, the NLRP3 inflammasome is the one
that has been most characterized (Toldo & Abbate, 2018). Similar to other inflammasomes, the
NLRP3 inflammasome can aptly be described as a finely regulated macromolecular protein
complex that activates a caspase -- caspase-1, and processes and releases pro-inflammatory
cytokines such as IL-1ß and IL-18. Furthermore, what makes the NLRP3 inflammasome an
important topic of research is the pathophysiological role it plays in acute to chronic
inflammatory responses that contribute to many different inflammatory diseases, as well as its
ability for sensing a wide variety of both intracellular danger and extracellular alarmin signals
(Franchi et al., 2012). The following includes a list of common PAMPs and DAMPs (NLRP3
agonists/stimuli):
•

DAMPs = MSU (monosodium urate) crystals, Ca++ influx, mROS (mitochondrial
reactive oxidative species), extracellular ATP (eATP), uric acid, cholesterol,
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hydroxyapatite crystal, silica, aluminum salts, asbestos, and fatty acids
(Franchi et al., 2012)
•

PAMPs = pathogens that include viruses (influenza A), bacteria (LPS, Neisseria
gonorrhoeae), gram-negative bacteria, and bacterial toxins like nigericin and
maitotoxin. Broz and Dixit have suggested that low intracellular potassium
concentrations that occurs from potassium release (K+ efflux) is associated with
all NLRP3 activators, and thus may one day be proved to be sufficient enough on
its own to trigger NLRP3 activation (Broz & Dixit, 2016) (Muñoz-Planillo et al.,
2013).

Additionally, these DAMPs/PAMPs are
responsible for binding to and activating
membrane-bound Toll-like receptors (TLRs).
Once TLRs in the membrane are activated the
resulting signal produced by DAMPs or
PAMPs are transmitted into the cell and
towards the nucleus as a downstream signal that
is mediated by myeloid differentiation factor-88
(MyD88) and interleukin-1 receptor-associated
kinase -1, -4 (IRAK1/4) which will activate
NF-𝜅B activity resulting in gene expression of
the NLRP3 inflammasome components and
proteins (Dagenais et al., 2012).
Figure 2: NLRP3 priming step (signal 1) and triggering
step (signal 2) (O’brien et al., 2014)
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The three NLRP3 (cryopyrin) inflammasome components produced are a sensor protein (NODlike receptor), adaptor protein (ASC), and an effector protein (caspase-1), which come together
by way of homotypic pyrin domain (PYD-PYD) and caspase recruitment domain (CARDCARD) interactions (Lu et al., 2014). Before detailing the two-step process of activating and
forming the NLRP3 inflammasome below is a brief summary detailing the components and
proteins involved in regulating its formation.

The first component of the NLRP3 inflammasome serves as the sensing component
which consists of NLRP3 itself. NLRP3 contains a leucine-rich repeat domain at the C-terminal,
an NLR/NBD/NACHT domain at its center, and a
pyrin domain at the N-terminal responsible for
binding to the second component of this
inflammasome (Martinon et al., 2006).
The second NLRP3 inflammasome component is
the apoptosis speck-like protein containing a CARD
(ASC) which serves as the adaptor protein. The
adaptor protein ASC consists of a pyrin domain
(PYD) and a caspase activation and recruitment
Figure 3: The NLRP3 components

domain (CARD). The function of ASC is to help
recruit procaspase-1 for the purpose of associating ASC and procaspase-1 with NLRP3, thus
bridging the sensor component (NLRs) with the downstream adaptor and effector (caspase-1)
(Martinon et al., 2006).
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The third component, caspase-1, is a cysteinyl aspartate-specific protease. Caspase-1 is
initially produced as an inactive precursor pro-caspase-1. Pro-caspase-1 consists of a CARD,
p20, and p10 subunits. After pro-caspase-1 is proteolytically cleaved, two p20 and two p10
subunits will assemble into the active caspase-1, a heterotetramer that is responsible for cleaving
pro-IL-1ß and pro-IL-18 to IL-1ß and IL-18 respectively and inducing pyroptosis, a cell death
process that will be further described in a later section (Broz et al., 2010)
In addition to the three main components that form the NLRP3 inflammasome, there are
other proteins such as Nek7, MARK4, and MAVs that have recently been investigated and
suggested to regulate NLRP3 inflammasome formation and activation.
Nek7 is a serine-threonine kinase and member of the family of mammalian NIMA-related
kinases (Neks) (De Souza et al., 2015) (He et al., 2016). According to research findings, Nek7
contributes to mitotic spindle assembly during early mitosis by localizing to the centrosome to
ensure mitotic progression (De Souza et al., 2015) (Schmid-Burgk et al., 2016). In addition,
Nek7 is an NLRP3-binding protein that acts downstream of potassium efflux and is presumed to
regulate the assembly and activation of the NLRP3 inflammasome (Schmid-Burgk et al., 2016).
A study in 2016 showed that when Nek7 is absent, NLRP3 inflammasome response is blunted as
evidenced by lower levels of caspase-1 and IL-1ß release. This study also showed that Nek7 only
affects the NLRP3 inflammasome, thus displaying specificity in that no other inflammasomes
(i.e. NLRC4 nor AIM2) showed marked effects by Nek7 binding (Schmid-Burgk et al., 2016)
Microtubule-affinity regulating kinase 4 (MARK4) is an evolutionarily conserved protein
whose function is to regulate microtubule dynamics through phosphorylating microtubule
associated proteins (MAP) (Trinczek et al., 2004). Additionally, Li et al. have shown that
MARK4 are important in regulating NLRP3 inflammasome sorting and activation. The manner
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MARK4 regulates NLRP3 inflammasome activation is suggested to be by binding to NLRP3 and
driving it to the microtubule-organizing center (MTOC), the site of NLRP3 inflammasome
activation, via microtubule-based transport (Li et al., 2017).
Mitochondrial anti-viral signaling proteins (MAVS) is another protein that is presumed to
associate with the NLRP3 inflammasomes and facilitate its oligomerization. A 2013 study
showed that when knocking down MAVS expression in THP-1 and mouse macrophages, there
was an attenuation of NLRP3 inflammasome activation. Furthermore, the study ultimately
suggest that MAVS facilitates the recruitment of NLRP3 to the mitochondria and may enhance
its oligomerization and activation by bringing it in close proximity to mROS (Park et al., 2013;
Subramanian et al., 2013)

1.2.1 NLRP3 Inflammasome Formation Pathway
The activation and formation of the NLRP3 inflammasome require two independent steps
that are labeled as the priming and triggering steps. The main objective of the priming step is to
induce the expression of NLPR3 inflammasome components via signaling pathways from the
TLRs on the cell membrane and NF-𝜅B activation, thereby priming the cells to respond in the
event of injury or pathogen exposure. Therefore, when extracellular primary signals, created by
cellular debris or microbial products (DAMPs/PAMPs), bind to and stimulate Toll-like receptors
(TLRs) located on the cell membrane, downstream signaling will activate the NF-𝜅B activity.
NF-𝜅B (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex
located in the cytoplasm that is capable of controlling cytokine production, and DNA
transcription (i.e. gene expression) resulting in the translation and production of inflammasome
components and cytokines such as NLRP3, ASC, pro-caspase-1, pro-IL-1ß, and pro-IL-18.
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Furthermore, as mentioned previously the downstream signaling that activates NF-𝜅B activity in
the nucleus is mediated by MyD88 and IRAKs. Despite primary signals activating gene
expression and formation of the individual NLRP3 components during the priming step, NLRP3
inflammasome activation, oligomerization, and IL-1ß processing do not occur without a
trigger/distress signal (Kelley et al., 2019).
According to experimental studies, one example of a trigger/distress signal capable of
activating the NLRP3 inflammasome has been the production of mitochondrial reactive oxygen
species (mROS) resulting from mitochondrial damage and oxidative stress (Muñoz-Planillo et
al., 2013) (Dagenais et al., 2012). It has been suggested that mROS production not only induces
NF-𝜅B-dependent gene expression seen in the priming step, but also NLRP3 inflammasome
oligomerization that prepares the cell for inflammasome activation (Dagenais et al., 2012)
Another example of distress signals capable of activating the NLRP3 inflammasome is
K+ efflux and cathepsin B release resulting from lysosomal destabilization. K+ efflux can also
result from an increase in cell death that causes extracellular ATP (eATP), a byproduct of cell
death, to attach to cells with P2X purinoreceptor 7 (P2X7) and induce inflammasome formation
(Mezzaroma et al., 2011) (Franchi et al., 2012). Following the increase in K+ efflux and the
resulting lowered K+ intracellular concentration, a cytosolic serine/threonine-protein kinase
(Nek7) senses K+ efflux and subsequently regulates the oligomerization and recruitment of
NLRP3 components (Schmid-Burgk et al., 2016).
Once the NLRP3 oligomerization process is induced, a circular structure is formed with a
central core that becomes the site of ASC polymerization. Originating from this central core of
polymerized ASC, a large number of pro-caspase-1 enzymes will be recruited, cleaved, and
activated into caspase-1 filaments that form a star-like structure that consists of numerous
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caspase-1 enzymes capable of enzymatically cleaving inactive pro-inflammatory cytokines proIL-1ß and pro-IL-18 into active pro-inflammatory cytokines IL-1ß and IL-18 respectively. In
addition, activated caspase-1 cleaves gasdermin D (GSDMD) which induces pyroptosis, a
programmed cell death responsible for pore formation and the release of pro-inflammatory
cytokines and intracellular/cytoplasmic content that further induces pro-inflammatory responses
(Swanson et al., 2019) (Takahashi, 2019).

W

Figure 4: Structure of the NLRP3 oligomer

1.2.2 IL-1 Family Pro-inflammatory Cytokines Release Processes
Cytokines make up a large group of proteins that are released by cells of the immune
system. Some examples of cytokines include chemokines, interferons, TNFs, and interleukins
(ILs). The function and release of cytokines are important in mediating the signaling pathways
involved in immunity and inflammation. To induce their effects on signaling pathways,
cytokines can be released by a general conventional model, or a non-conventional model.
Through the general conventional model, which describes how most cytokines are
secreted out of the cell, cytokines are first encoded and synthesized by genes that are inducible
by inflammatory transcription factors (TFs) like NF-𝜅B, and AP-1 (Smale & Natoli, 2014). Once
synthesized, cytokines that contain N-terminal secretion sequences will be able to insert into the
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endoplasmic reticulum (ER) in a co-translational manner (Lieberman et al., 2019). From the ER,
cytokines will eventually be released into the extracellular space where they then bind to their
appropriate receptors and promote inflammatory responses (Lieberman et al., 2019).
The other form of extracellular cytokine release, releases the most potent molecules of
the innate immune system, the IL-1 family cytokines(i.e. IL-1⍺, IL-1ß, IL-18, and 8 other
cytokines), through a process mediated by Gasdermin D (GSDMD), a pore-forming protein that
consists of a C-terminus that auto-inhibits the pore-forming activity of its N-terminus (Kayagaki
et al., 2015). Perhaps the most important cytokine released by this form of cytokine release is IL1ß, a pro-inflammatory cytokine that is initially formed as an inactive precursor. When activated
IL-1ß functions not only as a potent pyrogen (a substance that produces fever) but also as an
important signal that induces the synthesis and expression of several hundred downstream/
secondary inflammatory mediators (Dinarello, 2011). To induce these effects extracellular
signals must first activate the NLRP3 inflammasome leading to autocatalytic activation of its
effector -- caspase-1. Upon activation, caspase-1 proteolytically cleaves pro-IL-1ß, pro-IL-18,
and Gasdermin D resulting in mature IL-1ß and IL-18 as well as Gasdermin-D’s N-terminal
fragment that is now capable of forming pores within the cell membrane (Liu et al., 2016). In
addition, caspase-1 is also known to cleave several proteins from the Krebs cycle which triggers
a dramatic decrease in cell energy production resulting in cell swelling and rupture (Shao et al.,
2007). Consequently, the loss of cell membrane integrity resulting from the formation of a pore
by GSDMD, cell swelling, and rupture of the membrane allows for the release of intracellular
contents and pro-inflammatory cytokines into the extracellular space, a cell death process also
known as inflammasome-mediated pyroptosis (Lamkanfi & Dixit, 2014; Shi et al., 2015).
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1.3 The Role of the NLRP3 Inflammasome following Myocardial Injury
The role of cardiac inflammation, following myocardial injury, is to restore homeostasis
by eliminating and removing offending agents (cell debris and dead cells/tissue) from the area of
injury, which helps to bring about healing and wound repair by way of scar formation to the
injured myocardium. However, several reports have now demonstrated that excessive
inflammation modulated by the NLRP3 inflammasome, and IL-1ß processing has a role in
pathophysiological processes that contribute to AMIs, cardiac remodeling, and compensatory
mechanisms leading up to HF (Kawaguchi et al., 2011; Mezzaroma et al., 2011; B. W. Van
Tassell, Toldo, et al., 2013).
Beginning with the response to necrotic and apoptotic cell death that occurs during an
acute myocardial infarction; studies show that the innate immune system utilizes inflammatory
inducers (DAMPs released from necrotic cells: eATP, K+ efflux etc.), membrane sensors (PRRs:
TLRs), cytosolic sensors (NLRP3 inflammasomes), and cytokine release (IL-1ß, IL-6, IL-18) to
initiate enhanced inflammatory responses (Land, 2015). Responses, that cause local surges of
pro-inflammatory cytokines to significantly amplify/exacerbate sterile inflammatory responses
by inducing chemotactic recruitment of immune cells (neutrophils, macrophages, and fibroblasts)
to the infarcted myocardium, and activating the NLRP3 inflammasomes in leukocytes and
cardiac resident cells. Consequently, an enhanced inflammatory response, modulated by NLRP3
inflammasome, leads to increased inflammatory cell death (pyroptosis), additional loss of
functional myocardium, further dysregulation in recovery processes (fibrotic non-functional scar
formation) and systolic dysfunction that can persist and lead to systemic inflammation seen AMI,
adverse ventricular remodeling, and HF (Toldo et al., 2018).
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The potential of limiting/attenuating the inflammatory response to help in cardiovascular
diseases has led to early experimental studies investigating broad anti-inflammatory
interventions using glucocorticoids (Metz et al., 1986) and NSAIDS (Kalkman et al., 1995) and
later targeted anti-inflammatory interventions that targeted cytokines, CRP, and NLRP3, some of
which are discussed and referenced in a later section. Thanks to what was learned from these
studies, many current studies have developed new pharmacological drugs to target the NLRP3
inflammasome and its end products (IL-1ß and IL-18) with the goal of determining the efficacy
that targeted anti-inflammatory interventions could have on decreasing cell death, limiting LV
enlargement after an AMI, and overall reducing the risk/incidence of heart failure (Mezzaroma et
al., 2011) (B. W. Van Tassell et al., 2017)

1.4 Goal of the Study
When applied in a timely manner, reperfusion strategies in the form of percutaneous
coronary interventions (PCI), anti-thrombolytic medications, and implantation of stents, have
drastically improved survival rates and overall prognosis of AMI patients. However, there are
still a number of patients that do not receive reperfusion treatment during the appropriate
therapeutic window of time, as well as patients with comorbidities such as diabetes, obesity,
advanced age, hypertension, and large infarct sizes, that overall impair the efficacy of GDMT
and significantly increases the risk of developing further myocardial injury, adverse ventricular
remodeling, and heart failure.
In order to address these concerns, multiple experimental studies along with this present
study are investigating the efficacy of utilizing pharmacological strategies to mitigate NLRP3-
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modulated inflammatory signals that promote further myocardial injury in cardiovascular
diseases.
In contrast to studies investigating the anti-inflammatory effects of targeting downstream
NLRP3 mediators of inflammation (IL-1 receptors, IL-1ß, IL-6), this present study was designed
to utilize OLT1177 (dapansutrile), a recently developed NLRP3 inhibitor, to target and inhibit
the upstream NLRP3 formation process thereby resulting in less caspase-1 being activated, less
IL-1ß produced, and overall a decreased sterile inflammatory response. Furthermore, evidencebased research from a previous study suggests that OLT1177, when given promptly to mice
following ischemia-reperfusion injury from a transiently ligated AMI, was capable of reducing
infarct size and caspase-1 activity, as well as preserving cardiac systolic function thus confirming
the potential clinical translational value of utilizing OLT1177 as a cardioprotective strategy after
myocardial injury (Toldo et al., 2019). Additionally, previous studies have shown that chronic
IL-1ß activity promotes adverse cardiac remodeling, and that IL-1ß inhibition given in the
chronic phase of post-AMI remodeling, improves ventricular remodeling and ß-adrenergic
responsiveness as well as reduces ventricular filling pressures (Mezzaroma et al., 2011)
Hence, we hypothesize that by administering OLT1177 to inhibit the NLRP3
inflammasome after a myocardial injury we will not only prevent the NLRP3 inflammasome
from promoting aberrant inflammasome signaling production, but also mitigate the inflammatory
response, thereby improving cardiac remodeling and limiting heart failure. To evaluate this
hypothesis, we examined the effects of OLT1177 throughout a 10-week time period in mice
following a large nonreperfused AMI and our specific aims for this study included:
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1. Measuring the physiological benefit that OLT1177 has on ejection fraction, and
cardiac remodeling through the use of transthoracic echocardiography (TTE)
evaluation.
2. Measuring the effects of OLT1177 on preserving the heart’s contractile reserve and ßadrenergic responsiveness through the use of isoproterenol challenge and TTE
evaluation.
3. Assessing the physiological benefits that OLT1177 has on limiting systolic and
diastolic dysfunction through the use of LV catheterization (measuring LVEDP, +dP/dT,
-dP/dT, and peak systolic pressure).
Currently, there are no selective NLRP3 inhibitors that are clinically available at this time, thus it
is our aim that the knowledge gained from this research will bring us one step closer to finding
safe and effective ways to use a novel therapeutic class of NLRP3 inflammasome inhibitors to
slow adverse LV remodeling and improve clinical outcomes.

1.5 OLT1177 Therapy
OLT1177 (dapansutrile) is a ß-sulfonyl
nitrile molecule designed to inhibit the NLRP3
inflammasome’s capability of producing IL-1ß and
Figure 5: OLT1177 structure

IL-18 inflammatory cytokines. A previous study by Marchetti and colleagues described the
specificity of OLT1177, by demonstrating that it had no effect on other inflammasome types
such as AIM2 nor NLRC4 inflammasomes (Marchetti, Swartzwelter, Gamboni, et al., 2018b).
Additional findings from this study have shown that OLT1177 is safe in humans, therefore its
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unique inhibitory effect on the NLRP3 inflammasome has been a topic of research since its
development in 2017 due to its potential for treatment of IL-1ß- and IL-18-mediated diseases.

1.5.1 Routes of Administration
OLT1177’s routes of administration used in previous and current studies include the
following: oral route (enriched diet and capsule form), injection route (intraperitoneal), and oral
gavage. For oral OLT1177 administration, OLT1177-enriched diet (3.75g OLT1177 per kg of
food or 4.5g OLT1177 per kg of food) has been used in previous murine studies (Marchetti,
Swartzwelter, Gamboni, et al., 2018a; Toldo et al., 2019) while oral OTL1177 capsules used in
phase I-II clinical trials are currently being investigated in human heart failure patients (clinical
trial identifier: NCT03534297)
In regards to the injection route of administration, OLT1177 injections into the peritoneal
cavity (i.p. injections), have been primarily used in murine studies by first solubilizing crystalline
OLT1177 with sterile saline and subsequently injecting OLT117 using the following doses in
mice: 6, 60, 100 or 600 mg/kg OLT1177 i.p. dose (Toldo et al., 2019), or 200mg/kg OLT1177
i.p. (Sánchez-Fernández et al., 2019). Similarly, oral gavage of OLT1177 involves solubilizing a
dosage of OLT1177 (60, 600mg/kg) but instead of using saline, it is solubilized with distilled
water and subsequently administered to mice (Marchetti, Swartzwelter, Koenders, et al., 2018).

1.5.2 OLT1177 Effects and Mechanism of Action
Much of what is known regarding the effects and mechanism of action of OLT1177
comes from a 2017 report by Marchetti et al. In this report Marchetti and colleagues describe
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their results from a phase 1 clinical trial that involved 35 healthy human subjects. Overall, the
results from this clinical trial and pharmacokinetic studies demonstrated that OLT1177 at
different dosages (100, 300, and 1000mg capsules): has a long half-life (approx. 23 hrs.), is safe
(showing no organ toxicities) and well tolerated. This report also contained the results from in
vitro, in vivo, and whole cell-patch clamp studies.
From in vitro studies on human blood-derived macrophages (MBDM), murine
macrophage cell line, and freshly isolated human blood neutrophils, results demonstrated that
OLT1177: specifically targets the NLRP3 inflammasome, prevents NLRP3 inflammasome
formation by inhibiting ATPase activity, suppresses caspase-1 activity and IL-1ß and IL-18
release, and has no effect on TNFα and on the priming step of NLRP3 formation. Furthermore,
evidence that OLT1177 prevents NLRP3 inflammasome formation was provided through the use
of immunoprecipitation and FRET analysis on J774A.1 cells. The results from this experiment
demonstrated that OLT1177 prevents NLRP3 oligomerization and activation by directly
inhibiting NLRP3 inflammasome’s ATPase activity necessary for the recruitment and
association of NLRP3-ASC and NLRP3-caspase-1 (Duncan et al., 2007). Without these domain
associations, NLRP3 oligomerization is inhibited leading to a reduction in caspase-1 activity, the
release of mature inflammatory cytokines (IL-1ß and IL-18), as well as in pyroptotic cell death.
The results from in vivo studies on mice that had undergone LPS-induced systemic
inflammation, demonstrated that OLT1177 reduces the severity of systemic inflammation as
evidenced by decreased levels of chemokines and cytokines in lung, liver, spleen, and skeletal
muscle tissues. In addition, results from in vivo studies demonstrated that OLT1177 increases
oxidative metabolism. By way of examining excised muscle tissue, OLT-treated mice displayed
an increased reduced glutathione (GSH) and oxidized glutathione (GSSG) ratio, indicating an
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improved glutathione homeostasis that is important in antioxidant effects and in oxidative
metabolism.
Lastly, the report described utilizing whole-cell patch-clamp technique on human-LPS
primed monocytic U937 cells treated with OLT1177 and found that OLT1177 does not inhibit
the K+ ion current change (K+ efflux), a common activator of the NLRP3 inflammasome. As
mentioned earlier, activation of P2X7 receptor by eATP (a byproduct of cell death) results in K+
efflux from the cell as well as an expected current change to identify while utilizing the wholecell patch-clamp technique. Consequently, the results from the patch-clamp study led the
investigators to conclude that OLT1177 must inhibit the NLRP3 inflammasome by a mechanism
downstream of P2X7 receptor activation.
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CHAPTER 2: Methods and Materials
2.1 Ethical Approval
All experimental procedures in this study were performed in accordance with the “Guide
for the Care and Use of Laboratory Animals” published by the National Institutes of Health (8th
ed. revised 2011). The study protocol was approved by the Virginia Commonwealth University
Institutional Animal Care and Use Committee.

2.2 Study Design
The main variables that this study tested for in mice with a nonreperfused AMI, are the
changes in a 10-week time period that occur to cardiac function (systolic and diastolic function)
LV cardiac remodeling, and contractile reserve.
In this present study 60 adult male Imprinting Control Region (ICR) mice (8 weeks old)
of 35-45g of weight, supplied by Envigo (Indianapolis, IN) underwent an open-heart surgical
procedure. Of these, 54 mice underwent an experimental AMI via permanent ligation of the left
coronary artery near its origin (proximal), while the remaining 6 mice underwent a sham
operation procedure. Three days after inducing the experimental AMI or sham procedure, the
infarct size and cardiac remodeling of the surviving mice (n=35, 58%) were assessed noninvasively via transthoracic echocardiogram (TTE). Based on these echocardiogram values, mice
were assigned, utilizing this study’s inclusion criteria and comparative analysis, into 1 of 4
groups each with 1 of 3 different diets to eat from for 10 weeks. These 3 different diets were
low-dose OLT1177 diet (Group 1), high-dose OLT1177 diet (Group 2), and standard diet
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(Groups 3 and 4). Furthermore, all three diets were provided by Research Diets, Inc (New
Brunswick, NJ) and administered to mice 1 week after experimental AMI surgery, and
repeatedly added throughout the duration of this 10-week study.
At 4-weeks and 10-weeks, all surviving mice (n=28, 47%) underwent a transthoracic
echocardiogram along with an isoproterenol challenge to test the heart’s contractile reserve.
At the end of 10 weeks, 2 of 10 mice (20%) mice had died in the OLT 3.75 gr/kg group, as
compared with 2 of 9 mice (22%) in the OLT 7.5 gr/kg group, 3 of 10 mice (30%) in the
standard diet group, and 0 of 6 (0%) in the sham-operated group.
Lastly, the mice underwent an invasive LV catheterization procedure and then euthanized
by pentobarbital overdose. The hearts were then explanted, along with plasma and stored in a
freezer (-80C) for future ELISA analysis.

2.2.1 Experimental AMI Model Procedure
The experimental AMI model used in this study was performed under sterile conditions
and involved permanently ligating the left anterior descending coronary artery near its origin. For
the purpose of our study, this nonreperfused AMI model was utilized to simulate the drastic
changes that occur following a myocardial injury such as adverse cardiac remodeling in the form
of ischemic dilated cardiomyopathy and LV hypertrophy. To accomplish this complex, invasive,
and high-risk surgery, a skilled investigator performed these surgical procedures utilizing the
following protocol.
Each mouse was anesthetized intraperitoneally with the injection of sodium pentobarbital
(50-70mg/kg) and subsequently shaved in the left chest area. Next, the mouse was placed and
secured in a supine position, intubated, and placed in the right lateral decubitus position. The
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mice were connected to a positive-pressure ventilator. The tidal volume of this ventilator was set
at 0.25ml, and the respiratory rate was adjusted to 133cycles/min. A left thoracotomy (a surgical
procedure allowing access to the thoracic organs: heart and lungs) was performed in the 4th
intercostal space. The right lateral decubitus position also allowed access for a pericardiectomy
(surgical removal of part or most of the pericardium). Once the heart was exposed, the left
anterior descending coronary artery was identified and permanently occluded with the use of a 70 silk suture tied around the coronary artery. After each coronary artery occlusion, the thoracic
cavity was closed with sutures and the mice were extubated. The mice were then left to recover
on heating pads and slow-release buprenorphine (1mg/kg) was administered. Once recovered,
the mice were housed under climate-controlled conditions at a 12-hr light/dark cycle and
provided with standard mice chow/food and water for the next 7 days, wherein afterward their
diet was changed to either standard diet or diet containing low- or high-dose OLT1177.
Furthermore, the mice that survived the experimental AMI procedure showed exceptional
resilience in the form of eating, drinking, and moving around in their cages normally, and
without much discomfort.
In total 54 mice underwent the experimental permanent ligation AMI, while the
remaining 6 mice underwent a sham operation procedure that included every step in the protocol
except the left coronary artery ligation. A summary of the mortality rate in mice after the AMI
procedure (post-operative period) is seen in the following table:
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Table 1: The mortality, survival, and incidence of infarction before setting up
experimental groups
Attempted open heart surgeries.......................................................60
Survival of open-heart surgery + 3d ECHO...................................35 of 60 (58%)
Attempted AMI permanent occlusions...........................................54 of 60 (90%)
Initial Incidence of infarction (successful occlusions)................... 29 of 54 (54%)
Unsuccessful occlusion (i.e. LMI).................................................1 of 54 (0.02%)
Operative deaths (during AMI or ECHO)......................................11 of 60 (18%)
Late deaths (~1-3d after ECHO).....................................................13 of 60 (22%)
Note: the mice that died in the post-operative period or had unsuccessful occlusions
were excluded from the remainder of the experimental results, analyses, and tables.

2.2.2 Test Subject and Inclusion Criteria
Three days (72 hrs.) after AMI surgery, the surviving mice (n=35, 58%) underwent
transthoracic echocardiography (TTE). In our present study, TTE was performed three times
throughout 10 weeks to assess cardiac function, infarct size, and cardiac remodeling in a noninvasive manner. The results from the initial TTE were particularly important in allowing us to
assess and determine which mice would be part of the study and also set up different groups
based on our inclusion criteria and exclusion criteria.
The inclusion criteria of this study consisted of the following: mice with a large
nonreperfused anterior infarct (> 4 akinetic segments involving the anterior wall), an enlarged
ventricle (left ventricular end-diastolic diameter [LVEDD] > 4.4mm), and systolic dysfunction
(left ventricular ejection fraction [LVEF] < 40%). Our exclusion criteria consisted of mice that
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did not meet the inclusion criteria such as mice with a lateral myocardial infarction (LMI), mice
that underwent a sham operation, and mice that did not survive the AMI procedure.

2.2.3 Selection of Control and Experimental groups
After the assessment of the initial 3-day ECHO values, these mice were assigned to four
different groups by an investigator not involved in the assessment of endpoints. Below is a
description of the four groups and the number of mice that survived the full 10 weeks. Note:
these are the mice whose ECHO and LV catheterization values were utilized for this study’s
results, tables, and figures.
At the end of 10 weeks, all sham-operated mice (n=6), and 41% of the mice (n=22) that
had undergone the experimental AMI were alive. Whereas 59% of the mice (n=32) that
underwent the experimental AMI had died: during the initial AMI procedure (n=11), shortly after
echocardiogram(s) (n= 13), or throughout the 10 weeks due to causes linked to the change in diet
(from regular chow to the experimental OLT diet) (n=1), or not surviving anesthesia during
week-4 and week-10 echocardiogram assessments (n=4). Furthermore, two of the mice were
euthanized due to succumbing to fighting wounds (n=1), or illness (n=1), and one mouse (n=1)
was excluded for having an LMI.
•

Group 1 consisted of 10 mice that underwent an AMI procedure. The diet that these mice
received for 10 weeks was a diet containing OLT1177 (3.75 gr/kg). This diet was also
referred to as the low-dose OLT diet and was gray in color.

•

Group 2 consisted of 9 mice that underwent an AMI procedure. The diet that these mice
received for 10 weeks was a diet containing OLT1177 (7.50 gr/kg). This diet was also
referred to as the high-dose OLT diet and was yellow in color.
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•

Group 3 consisted of 10 mice that underwent an AMI procedure. The diet that these mice
received for 10 weeks was the control/standard diet. This diet contained no OLT1177 and
was green in color.

•

Group 4 consisted of 6 mice that underwent a sham operation. The diet that these mice
received for 10 weeks was the control/standard diet. This diet contained no OLT1177 and
was green in color.

2.2.4 Treatment with OLT1177 Diet
The experimental treatment tested in this study was OLT1177, a pharmacological NLRP3
inflammasome inhibitor, that was supplemented/admixed into mice chow (0.5” pellets) and
color-coded by Research Diets, Inc (New Brunswick, NJ). This diet, which was supplemented
with either low- or high-dose OLT1177 (3.75g or 7.50g of OLT1177 per kg of food), was
administered 1-week post-AMI to experimental Groups 1 and 2 respectively. Research Diets, Inc
(New Brunswick, NJ) also provided the control diet which was labeled as standard/control diet.
This control diet did not contain OLT1177 and was administered to Group 3 (control group
mice) and Group 4 (sham-operated mice)
Throughout the remainder of this 10-week study, the survival of the animals and the
average food consumption of every cage was assessed and recorded every ~1-3 days. To ensure
the mice were eating sufficiently, food was added regularly, and further monitoring was done by
weighing and recording the weight of each mouse once a week for 10 weeks. In addition, all
cages were examined daily, and changed once a week by employees of the Department of
Animal Resources.
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Weekly Food Consumption
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Figure 6: Average weekly food consumption of all four groups during the 10-week study

Weekly Body Weight
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Figure 7: Average body weight of all four groups recorded each week during the 10-week study
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As can be seen in Figures 6 and 7, during the first 2-3 weeks of the study, both OLTtreated mice groups consumed considerably lower amounts of their diet, especially the high-dose
OLT-treated group. Consequently, the high-dose OLT-treated group (Group 2) also had lower
weights than other mice groups. One possible reason for this difference in food consumption and
body weight can be due to a period of acclimation to a new diet, with preferences of flavors
playing a possible role. Nevertheless, food consumption and body weight of Group 2 mice
gradually increased to comparable levels of the other mice groups in the study.

2.3 Transthoracic Echocardiography (TTE)
Transthoracic echocardiography is a noninvasive imaging technique that allows one to
monitor and visualize in real-time the heart’s morphology, infarct size, and function. To produce
images, echocardiography utilizes a piezoelectric crystal contained within a transducer to emit a
controlled high-frequency sound (ultrasound) waves that have the capability to travel through
any medium (Mohamed et al., 2010). This transducer is also responsible for detecting ultrasound
waves/echoes that are reflected back to the transducer from body tissues and converted into
electrical signals and images appearing on the echocardiography system screen. These echo
signals that are reflected from different body tissues differ in brightness depending on the density
of that particular body tissue. For example, dense tissues like pericardium will appear
white/bright, whereas hollow tissues like blood-filled chambers of the heart will appear black,
signifying that no echo signals were produced/reflected.
In this present study we utilized echocardiography to assess and monitor the changes and
dissimilarities in LV systolic function, infarct size, cardiac remodeling, and wall motion
abnormalities between the groups of mice eating the experimental diet (3.75 and 7.5 g/kg
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OLT1177) and mice eating the standard diet. In addition to the 3-day echocardiography, TTE
was also performed at 4-weeks and 10-weeks post-AMI. The echocardiography system that was
used in this study was the Vevo770 High Resolution in vivo micro-imaging system
(VisualSonics Inc, Toronto, Ontario) along with a transducer probe with a high transmit
frequency of 30-MHz (Respress & Wehrens, 2010). Note: for comparison, the typical range of
frequencies used in adult human echocardiography ranges from 2.0 to 5.0 MHz (Mitchell et al.,
2019)
On days when transthoracic echocardiography was performed, each mouse was mildly
anesthetized with pentobarbital (30-50 mg/kg) and shaved at the upper and lower chest area.
Following this, the mouse was secured and placed in a supine position on a warmed VEVO770
platform. While in the supine position the investigator, that performed and read all
echocardiograms, applied warmed ultrasound transmission gel on the animal’s chest to enhance
TTE image quality and next placed the transducer on the thoracic region to visualize the heart
from the parasternal short-axis view (Note: this investigator was blinded to treatment allocation).
While echocardiography has three different imaging modes (B-mode, M-mode, and
Doppler tissue imaging), for this study the animal’s hearts were visualized using B-mode (2-D
imaging). When the transducer was appropriately placed to see the parasternal short-axis (PSAX)
view, B-mode reliably produced grayscale maps/images of the heart that allowed us to visualize
ventricular wall motion abnormalities associated with infarcted myocardium (Lilly, 2013) and
estimate the size of the left ventricle (Mitchell et al., 2019). Estimating the size of the LV is
especially useful in assessing LV systolic function and cardiac enlargement (dilatation), thereby
allowing researchers and clinicians a way to monitor pathophysiologies and responses to
treatment in diseased hearts. From these images and M-mode tracing (Doppler data) the
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parameters that were evaluated were the left ventricular end-diastolic diameter (LVEDD) and left
ventricular end-systolic diameter (LVESD).
The manner in which infarct size and regional myocardial function were visually assessed
was by evaluating the regional wall motion and left ventricular (LV) wall thickening through the
usage of the 16-segment model of the left ventricle (LV) that allowed us to assess LV wall
motion and wall thickening (Pellikka et al., 2020). While other segmentation models are used
clinically, like the 17-segment and 18-segment models, we utilized the 16-segment model which
was recommended for studies assessing wall motion and not segments located at the tip of the
apex, whose wall would be imperceptible in our studies and thus irrelevant (R. Lang, L. Badano,
V. Mor-Avi, J. Afilalo, A. Armstrong, 2015).
Through this 16-segment model, the investigator individually counted, analyzed, and
graded the function of the 16-segments of the LV, giving a score of either 3 or 4 according to a
4-grade scoring system. This is especially useful when making visual assessments of LV
myocardial regions that are supplied by occluded coronary arteries and identified by the
reduction in motion (hypokinesis) or lack thereof (akinesis) in an ischemic, infarcted, or scarred
myocardial wall region (R. Lang, L. Badano, V. Mor-Avi, J. Afilalo, A. Armstrong, 2015). The
grades from this 16-segment model are described in Table 2. By averaging the scores of all
segments visualized, a wall motion score index was produced and used to estimate the size of the
infarct (Pellikka et al., 2020).
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Score

Wall Motion

Endocardial Motion

Systolic Increase in
Thickness

1

Normal

Normal

>50%

2

Hypokinetic

Reduced

<40%

3

Akinetic

Absent

<10%

4

Dyskinetic

Outward/Paradoxical

Thinning

Table 2: The 4-grade scoring system utilized alongside the 16-segment model.
(Pellikka et al., 2020).

During these LV wall thickening readings, an investigator also utilized a cursor on the
echo system screen to mark the location of the endocardial border during diastole and assess the
change that occurs to LV wall thickening during systole, which helped in estimating the
thickness of the LV wall. (Pellikka et al., 2020). From these images and M-mode tracing
(Doppler data), the parameters that were evaluated included anterior wall diastolic thickness
(AWDT), posterior wall diastolic thickness (PWDT), anterior wall systolic thickness (AWST),
and posterior wall systolic thickness (PWST).
The left ventricular structural parameters that were visually assessed with the use of TTE
were also utilized to calculate left ventricular fractional shortening (FS), ejection fraction (EF),
and LV mass.
LV fractional shortening is a calculated parameter that measures the functional capacity
that the heart is able to squeeze/contract. It was calculated utilizing the following formula:
LVFS = (LVEDD-LVESD) / LVEDD x 100
LV Ejection fraction is a measure of contractile function and it was calculated with the
Teichholz formula. To measure the left ventricular ejection fraction, the measured LV enddiastolic and end-systolic areas were measured with B-mode TTE and converted to volumes
LVESV and LVEDV. With these values the following formula is capable of calculating LVEF:
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LVEF = (EDV – ESV) / EDV x 100
However, when it comes to changes in shape from a physiologically ellipsoid to an adverse
dilated shape, the LVEF was derived utilizing the Teicholz formula, a formula dependent on
estimating LV end-systolic and end-diastolic volumes to the third power of the diameter
multiplied by a factor of 1.047 according to the ellipsoid shape in which the length is twice the
diameter: (Toldo et al., 2019).
LVEF = [LVEDD^3 – LVESD^3] / LVEDD^3
LV mass is a strong predictor of cardiovascular events that is also calculated utilizing Mmode echocardiography parameters. Although there are several methods that can calculate the
LV mass, the method that was utilized in this study was the Linear Method. Through the Linear
Method, LV mass was calculated utilizing the Cube Formula, a geometric formula that
incorporates the 2D echocardiography linear measurements of LV diastolic diameter and wall
thickness to first calculate the volume of the LV myocardium. Then it converts the volume to
mass by multiplying the volume of LV myocardium by the myocardial density (approx.1.05
g/mL in humans)(R. Lang, L. Badano, V. Mor-Avi, J. Afilalo, A. Armstrong, 2015)
LV mass = 0.8 ⋅ 1.04 ⋅ [(IVS + LVID + PWT)^3 – LVID^3] + 0.6g
Note: IVS, interventricular septum; LVID, left ventricle internal diameter; PWT, inferolateral
wall thickness.

2.4 Isoproterenol Challenge
Immediately following the 4-week and 10-week echocardiogram, isoproterenol (20
ng/mouse) was injected intraperitoneally to each anesthetized mouse while in the supine position
on the VEVO770 platform for the purpose of assessing myocardial contractile reserve.
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Furthermore, at this point in the 10-week study all mice that underwent a permanent
ligated nonreperfused AMI would have also experienced adverse cardiac remodeling leading to
heart failure. As mentioned previously, cardiac remodeling is regulated by neurohormonal,
RAAS, and inflammatory signaling pathways, that are initially beneficial, but as time passes
becomes maladaptive leading to adverse ventricular remodeling and heart failure. Additionally,
as cardiac efficiency diminishes significant desensitization and downregulation of ß-adrenergic
receptors occurs leading to reduced responsiveness of the ß-adrenergic receptor system and loss
of contractility (Lohse et al., 2003).
Isoproterenol is a potent, synthetic β-adrenergic receptor agonist that has positive
chronotropic (increased HR) and inotropic (increased contractility) properties. As a result, we
utilized isoproterenol to characterize OLT1177’s effect on preserving systolic function,
contractile reserve, and ß-adrenergic sympathetic responses in OLT-treated mice. Through the
use of TTE, measurements were taken to calculate the percent increase in EF (contractile
reserve) and LVFS within 5 minutes after isoproterenol injection.

2.5 LV Catheterization Procedure
Eight days after the 10-week TTE, all surviving mice underwent LV catheterization, a
terminal procedure that was utilized to evaluate LV function in vivo.
In preparation for this procedure, all mice were anesthetized with pentobarbital (50-70
mg/kg) and shaved at the anterior neck region. After the preparation of the mice and surgical
environment, incisions were made in the neck area of each mouse. These incisions exposed the
vasculature of the neck area particularly the carotid arteries. Next, a pressure probe catheter
(Millar Inc., Houston, TX), also known as a Millar® Mikro-Tip® Pressure Transducer Catheter,
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was inserted into the right carotid artery and was further driven to the left ventricle of the heart to
measure intracardiac pressure-volume tracings. Additionally, when a catheter is inserted into a
blood vessel leading to the heart, each cardiac chamber produces a characteristic pressurevolume loop that is important in both locating the position of the probe catheter, as well as
deriving important in vivo physiologic information. Although the probe catheter is small, it was
extremely intricate and helpful in allowing us to measure and record the Peak systolic pressures
(PSP), LV end-diastolic pressures (LVEDP), and velocity of contraction and relaxation (+dP/dt
and -dP/dt). Furthermore, the values from this probe catheter were recorded (in real-time) and
measured using Labchart Pro 5 (Millar Inc., Houston, TX).

2.6 Timeline of the Study Protocol

10 weeks
3 days

28 days

70 days

SD/OLT 1177 Diet Administered
for daily consumption
Screening ECHO 3 days
post-AMI

Millar Catheter
Procedure
10-week ECHO
Contractile Reserve

4-week ECHO
Contractile Reserve

Permanent
Ligation of LAD

Figure 8: Timeline of the study protocol. LAD, Left anterior descending artery; SD, standard
diet; ECHO, echocardiography; contractile reserve, isoproterenol challenge.
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2.7 Statistical Analysis
All data presented in the following chapter utilized values derived from the procedures
and techniques explained in this chapter. Additionally, the values from these procedures and
techniques are presented as the mean and standard error of the mean. The differences between
mouse treatment groups were compared by utilizing two-tailed Student’s T-test. One-way
analysis of variance (ANOVA) was used for the comparison of two different doses and the
control condition with post-hoc Bonferroni’s test for multiple comparisons. Unadjusted p-values
are reported throughout, with statistical significance set at the 2-tailed 0.05 level (<0.05).
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CHAPTER 3: Results
3.1 The Effects of OLT1177 on Systolic Function
The left ventricular ejection fraction (LVEF) of all surviving mice were measured 3 days,
4-weeks, and 10-weeks post-AMI through the use of transthoracic echocardiography (TTE).
From these TTE measurements measuring LVEF at 3-days post-AMI (Figure 9), we see a
marked decrease in systolic function, as evidenced by the low mean LVEF (27.6  0.9%) and
LVFS (12.9  0.4%) of all mice groups that underwent permanent ligation of the left anterior
descending coronary artery (Table 3, 4, and 5). Whereas the mice group that underwent the sham
operation maintained normal ejection fractions (64.3  2.1%) and LV fractional shortening (34.8
 1.6%). After the assessment of the initial 3-day ECHO values, these mice were assigned to
four different groups.
Based on TTE measurement comparisons at 3-days and at 10-weeks post-AMI (Figure 9)
no significant differences in LVEF were noted between the OLT-treated mice groups and the
control diet mice group. Additionally, both low- and high-dose OLT-treated experimental groups
showed similar ejection fractions and downward trends in LVEF when compared to the control
group (22.6  1.8% in OLT 3.75gr/kg or 24.7  3.1% in OLT 7.50gr/kg vs 21.9  1.9% in
control group, P = 0.77, P = 0.44) (Figure 10). Therefore, these data indicate that OLT1177 had
no significant effect on the LVEF of OLT-treated mice.

48

LVEF 3 days and 10 weeks post-AMI
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#

50
40
30

*

*

*

#

#

20

*

*

*

10
0
Sham (N=6)
Control diet (N=7)
OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)

Sham

Control
Diet

OLT 3.75 OLT 7.50
gr/kg
gr/kg

3 days

Sham

Control
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Figure 9: LVEF, Left ventricular ejection fraction at 3-days and 10-weeks after permanent ligation of
the LAD coronary artery.

LVEF at 3 days, 4 weeks, & 10 weeks post-AMI
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Figure 10: LVEF, Left ventricular ejection fraction at 3-days, 4-weeks, and 10-weeks post-AMI scatter
plot
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3.2 The Effects of OLT1177 on Cardiac Remodeling
As expected, TTE measurements acquired at 3-days post-AMI show pronounced cardiac
remodeling in the form of LV dilatation and eccentric LV hypertrophy, as evidenced by the
significant increase in LVEDD, LVESD, and LV mass in all mice that underwent permanent
ligation of the left anterior descending coronary artery (Figure 11, 13, 15). Whereas shamoperated mice, when compared to treatment and control groups displayed a significantly
preserved LVEDD, LVESD, and LV mass, thus no cardiac remodeling.
LVEDD:
TTE parameters measured throughout the 10-week study show that both OLT-treated mice
groups and control group mice, when compared to the sham group, had significant increases in
LVEDD after 10 weeks: control group mice (6.38  0.26mm vs 4.07  0.10mm, P < 0.0005), low
dose OLT group mice (5.71  0.16 vs 4.07  0.10mm, P < 0.0005), and high dose OLT group
mice (6.13  0.22 vs 4.07  0.10mm, P < 0.0005) as seen in Figure 11.

LVEDD at 3 days and 10 weeks post-AMI
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OLT 7.50
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#

#

6
5

* p<0.005 vs sham
# p<0.0005 vs 3 days

4
3
2
1
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Sham (N=6)
Control diet (N=7)
OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)
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Sham

Control
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Figure 11: LVEDD, Left ventricular end diastolic diameter at 3-days and 10-weeks after permanent
ligation of the left anterior descending coronary artery.

50

Additionally, both low- and high-dose OLT-treated experimental groups displayed a similar
upward trend in LVEDD when compared to the control group (Figure 12). LVEDD TTE
measurements after 10 weeks suggests that both OLT-treated mice groups, when compared to the
control group, did not significantly attenuate ventricular enlargement.

LVEDD at 3 days, 4 weeks, & 10 weeks post-AMI
7
Control Diet
OLT 7.50 gr/kg
OLT 3.75 gr/kg

ECHO LVEDD (mm)

6
5

Sham

4
3
2
1

Sham (N=6)
Control diet (N=7)
OLT 3.75 gr/kg (N=8)
OLT 7.50 gr/kg (N=7)

3 days
1

4 weeks
2

10 weeks
3

Figure 12: LVEDD, Left ventricular end diastolic diameter at 3-days, 4-weeks and 10-weeks after AMI
surgery.

LVESD:
TTE parameters measured at 3 days and 10 weeks after permanent ligation surgery show that
both OLT-treated mice groups and control diet group mice had similar and significant percent
increases in LVESD: control group mice (+33%, P < 0.0005), low dose OLT group mice (+30%,
P < 0.0005), and high dose OLT group mice (+35%, P < 0.0005) as seen in Figure 13.
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LVESD 3 days and 10 weeks post-AMI
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Figure 13: LVESD, Left ventricular end systolic diameter at 3-days and 10-weeks after permanent
ligation of the left anterior descending coronary artery
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Figure 14: LVESD, Left ventricular end systolic diameter at 3-days, 4-weeks, and 10-weeks after
nonreperfused AMI surgery.
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LVESD TTE measurement after 10 weeks also demonstrated that neither low dose OLT-treated
mice (3.75gr/kg OLT), nor high dose OLT-treated mice (7.50gr/kg) had a significant effect on
attenuating ventricular enlargement in relation to LVESD when compared to the control group
(5.21  0.12mm in OLT 3.75gr/kg or 5.42  0.28mm in OLT 7.5 gr/kg vs 5.62  0.24mm
control group, P = 0.13 and P = 0.58 respectively) (Figure 13, 14).

Calculated LV Mass:
TTE measurements also allowed us to utilize ECHO values to calculate left ventricular mass.
TTE parameters measured at 3 days post-AMI (Figure 15) show that both OLT-treated mice
groups and control diet group mice, when compared to ECHO values measured at 10 weeks postAMI, had significant increase in LV mass: control group mice (110.5  6.0mg vs 187.1 
13.5mg, P < 0.05), low dose OLT group mice (104.4  3.4mg vs 157.5  12.1mg , P < 0.05),
and high dose OLT group mice (96.5  6.3 vs 180.4  17.5mg, P < 0.05). Similarly, from Figure
16, we see that the high-dose OLT-treated mice group and the control diet group show a similar
upward trend in LV mass throughout the 10-week study. Figure 16 also appears to show a
somewhat attenuated LV mass in low-dose OLT-treated mice, however this finding was not
significant when compared to the control group.
All things considered, Figure 15 shows that when comparing both OLT-treated mice
groups to the control group, OLT1177 had no significant effect on attenuating the gradual
increase in LV mass that occurs throughout the 10-week study.
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LV Mass at 3 days and 10 weeks post-AMI
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Figure 15: Calculated LV Mass at 3-days and 10-weeks after permanent ligation of the left anterior
descending coronary artery.
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Figure 16: Calculated LV Mass at 3-days, 4-weeks and 10-weeks after permanent ligation surgery

The significant increase in LV mass of all mice groups that underwent nonreperfused
AMI surgery, indicates that cardiac remodeling in the form of LV hypertrophy has occurred
(Figure 15 and 16). To determine whether concentric or eccentric LV hypertrophy occurred, TTE
measurements of LV mass along with LV diameters (LVEDD and LVESD) were evaluated.
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Based on these ECHO values, we determined that both OLT-treated mice groups and the control
diet group underwent eccentric LV hypertrophy, as evidenced by the increase in LV mass along
with an increase in diameters (LVEDD, LVESD) seen in Tables 3, 4, and 5. The increase in the
diameter or cavity of the left ventricle, as previously discussed, initially allows the heart to
accommodate more blood volume in order to maintain stroke volume and cardiac output.
However, as time passes, the continual increase in blood volume can lead to eccentric
hypertrophy and volume overload associated with systolic heart failure. On the other hand, had
TTE measurements shown that LV mass increased while the diameter (LVEDD) had not, it
would have been indicative of concentric LV hypertrophy resulting from significant thickening
of the heart muscle in the left ventricle.
Further evidence of Eccentric remodeling was paralleled by calculating the index of
Eccentric Remodeling:
Index of Eccentric Remodeling = (AWDT + PWDT) / LVEDD
Sham operated mice: (0.86 + 0.88) / 4.07 = 0.427
Control group mice: (0.47 + 0.99) / 6.38 = 0.229
Low dose OLT-treated mice: (0.47 + 1.01) / 5.71 = 0.259
High dose OLT-treated mice: (0.51 + 0.98) / 6.13 = 0.229
By inputting the corresponding TTE values seen in Tables 3, 4, 5, and 6 into the formula we see
that all mice groups that underwent nonreperfused AMI surgery display a lower index of
eccentric remodeling (when compared to sham operated mice) demonstrating an increase in LV
diameter along with a thinner LV wall. Thus, further indicating that eccentric LV hypertrophy
had occurred.
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Table 3: Left Ventricular Structural Parameters of Group 1 Mice (MI + 3.75g/kg OLT Diet)
3 days post-AMI
4 wks post-AMI
10 wks post-AMI
% Change (3d to 10wks)
N=
8
8
8
8
EDD (mm)
4.63  0.16
5.87  0.42
5.71  0.46
23.3% ↑
ESD (mm)
4.02  0.20
5.18  0.38
5.21  0.33
29.6% ↑
AWDT (mm)
0.55  0.06
0.42  0.04
0.47  0.08
-14.5% ↓
PWDT (mm)
0.89  0.08
0.97  0.20
1.01  0.08
13.5% ↑
AWST (mm)
0.57  0.06
0.42  0.04
0.48  0.10
-15.8% ↓
PWST (mm)
1.30  0.15
1.40  0.24
1.40  0.12
7.70% ↑
FS (%)
13.5  1.77
11.6  1.92
10.5  2.45
-22.2% ↓
EF (%)
28.4  3.66
24.4  3.74
22.6  4.96
-20.4% ↓
HR (bpm)
379.9  50.4
316.3  77.1
311.5  51.2
-18.0% ↓
Calc. LV Mass (mg)
104.4  9.54
151.0  25.7
157.5  34.3
50.0% ↑
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST,
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate.

Table 4: Left Ventricular Structural Parameters of Group 2 Mice (MI + 7.50g/kg OLT Diet)
3 days post-AMI
4 wks post-AMI
10 wks post-AMI
% Change (3d to 10wks)
N=
7
7
7
7
EDD (mm)
4.61  0.17
6.14  0.77
6.13  0.58
33.0% ↑
ESD (mm)
4.01  0.17
5.52  0.85
5.42  0.73
35.2% ↑
AWDT (mm)
0.55  0.07
0.46  0.07
0.51  0.06
-7.27% ↓
PWDT (mm)
0.81  0.16
0.89  0.19
0.98  0.16
21.0% ↑
AWST (mm)
0.58  0.08
0.47  0.08
0.51  0.07
-12.1% ↓
PWST (mm)
1.17  0.23
1.17  0.25
1.39  0.23
18.8% ↑
FS (%)
13.0  2.00
10.1  3.85
11.9  4.10
-8.46% ↓
EF (%)
27.9  4.34
22.1  7.88
24.7  8.20
-11.5% ↓
HR (bpm)
439.4  61.3
305.7  60.7
334.0  45.9
-24.0% ↓
Calc. LV Mass (mg)
96.5  16.7
161.6  49.0
180.4  46.2
86.9% ↑
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST,
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate.

Table 5: Left Ventricular Structural Parameters of Group 3 Mice (MI + SD Diet) i.e. Control
3 days post-AMI
4 wks post-AMI
10 wks post-AMI
% Change (3d to 10wks)
N=
7
7
7
7
EDD (mm)
4.83  0.41
5.99  0.58
6.38  0.69
32.1% ↑
ESD (mm)
4.24  0.37
5.47  0.61
5.62  0.64
32.5% ↑
AWDT (mm)
0.53  0.07
0.49  0.11
0.47  0.08
-11.3% ↓
PWDT (mm)
0.89  0.11
1.00  0.20
0.99  0.14
11.2% ↑
AWST (mm)
0.55  0.06
0.53  0.24
0.45  0.08
-18.2% ↓
PWST (mm)
1.29  0.19
1.37  0.17
1.39  0.21
7.75% ↑
FS (%)
12.1  2.19
8.43  3.20
10.4  2.30
-14.1% ↓
EF (%)
26.4  4.28
18.9  6.84
21.9  4.95
-17.1% ↓
HR (bpm)
400.0  55.6
351.7  62.8
312.1  56.2
-22.0% ↓
Calc. LV Mass (mg)
110.5  16.0
169.5  25.0
187.2  35.7
69.4% ↑
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST,
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate.
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Table 6: Left Ventricular Structural Parameters of Group 4 Mice (Sham + SD Diet)
3 days post-AMI
4 wks post-AMI
10 wks post-AMI
% Change (3d to 10wks)
N=
6
6
6
6
EDD (mm)
3.97  0.26
4.07  0.25
2.52% ↑
ESD (mm)
2.58  0.22
2.85  0.28
10.5% ↑
AWDT (mm)
0.80  0.09
0.86  0.09
7.50% ↑
PWDT (mm)
0.83  0.09
0.88  0.08
6.02% ↑
AWST (mm)
1.28  0.10
1.27  0.10
-0.78% ↓
PWST (mm)
1.20  0.12
1.29  0.15
7.50% ↑
FS (%)
34.8  3.97
30.2  3.49
-13.2% ↓
EF (%)
64.3  5.13
57.7  4.93
-10.3% ↓
HR (bpm)
407.8  78.7
413.0  87.3
1.28% ↑
Calc. LV Mass (mg)
95.3  20.1
107.6  17.0
12.9% ↑
Note: Values are Mean  SD; EDD, End diastolic diameter; ESD, End systolic diameter; AWDT, anterior wall
diastolic thickness; PWDT, posterior wall diastolic thickness; AWST, anterior wall systolic thickness; PWST,
posterior wall systolic thickness; FS, fractional shortening; EF, ejection fraction; HR, heart rate.

3.3 The Effects of OLT1177 on Contractile Reserve
Throughout this 10-week study, LV contractile reserve / ß-adrenergic response was
measured twice as a percent change at 4-weeks and 10-weeks post-AMI. At 4-weeks post-AMI,
both experimental OLT-treated mice groups and the control diet group were administered
isoproterenol (i.p.) immediately following TTE assessment. From Figure 17 we see that both
OLT-treated mice groups 3.75 gr/kg OLT and 7.50gr/kg OLT (when compared to the control
group) had noticeably greater contractile reserve and thus greater ß-adrenergic responses to
isoproterenol (+26  11% vs +14  10%, P<0.46) and (+31  10% vs +14  10%, P < 0.27)
respectively. Whereas control diet mice exhibited a blunted ß-adrenergic response to
isoproterenol (+14  10%).
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Figure 17: Contractile reserve assessment at 4 weeks after nonreperfused AMI surgery.

At 10-weeks post-AMI, both OLT-treated mice groups, the control group, and shamoperated mice were administered isoproterenol i.p. immediately following TTE assessment.
From Figure 18 and 19 we see that low dose OLT-treated mice (3.75 gr/kg OLT) when
compared to the control group mice displayed a significantly greater ß-adrenergic response and
LVEF percent increase (33  11% vs 9  7% P < 0.05) and LVFS percent increase (34  10% vs
4  6%, P < 0.05). Figure 18 also shows that high dose OLT-treated mice (7.50 gr/kg OLT) when
compared to control diet group mice displayed a significantly greater ß-adrenergic response and
LVEF percent increase (40  6% vs 9  7%, P < 0.005) and LVFS percent increase (41  7% vs
4  6%, P < 0.005) (Figure 19). Whereas the control diet mice, when compared to sham-operated
mice, exhibited a significantly blunted ß-adrenergic response to isoproterenol (9  7% vs 28 
4% LVEF, P<0.05). The significant percent increases of LVEF and LVFS, which were seen in
both OLT-treated mice groups when compared to the control group, suggests that OLT1177 had
a significant effect on restoring the contractile reserve and ß-adrenergic response after AMI
surgery.
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Figure 18: LVEF Contractile reserve assessment at 10 weeks after nonreperfused AMI surgery.
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Figure 19: LVFS Contractile reserve assessment at 10 weeks after nonreperfused AMI surgery.

3.4 The Effects of OLT1177 on Diastolic Function
Eight days after the 10-week TTE assessment, the cardiac function of all surviving mice
was assessed with the use of LV catheterization (Note: some mice [n=5] did not survive long
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enough to record LV catheterization values during this procedure). The principle parameter that
was measured was LV end diastolic pressure (LVEDP).
From these LV catheterization measurements (Figure 20), we see a greater degree of
diastolic dysfunction in control group mice, as evidenced by the significantly higher LVEDP
(10mmHg) displayed in comparison to all other mice groups.
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Figure 20: LV catheterization assessment of LVEDP, LV end diastolic pressure at ∼11 weeks after
nonreperfused AMI surgery.

Figure 20 also demonstrates that both OLT-treated mice groups (3.75 gr/kg OLT and 7.50gr/kg
OLT) and sham-operated mice displayed similar LV end-diastolic pressures. Thus, indicating
that treatment with OLT1177 3.75 gr/kg or 7.50 gr/kg led to the preservation of diastolic
function with a significantly lower LVEDP when compared to the control group (3.2  0.5
mmHg, or 4.5  0.5 mmHg vs 10.0  1.6 mmHg in standard diet; P<0.005 and P<0.009).
All things considered, the elevated filling pressures (LVEDP) in control group mice, can
be an indicator of heart failure. Whereas, a lower or normal LVEDP seen in the OLT-treated
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mice groups seem to suggest that OLT1177 treatment is effective at preventing the increase in
filling pressure due to diastolic dysfunction.

3.5 Chapter Summary
The general aim of our study was to assess the effects of OLT1177 on improving cardiac
function, cardiac remodeling, and contractile reserve. For this purpose, our experimental groups
were fed an OLT1177-enriched diet (3.75g or 7.50g of OLT1177 per kg of food) starting 1 week
after nonreperfused AMI surgery until the end of the 10-week experiment.
At the end of 10 weeks 2 of 10 mice (20%) mice had died in the OLT 3.75 gr/kg group,
as compared with 2 of 9 mice (22%) in the OLT 7.5 gr/kg group, 3 of 10 mice (30%) in standard
diet, and 0 of 6 (0%) in sham-operated mice. Our results from this study, taken from
transthoracic echocardiography, isoproterenol challenge, and LV catheterization, show that
control group mice (when compared to sham operated mice) displayed a significant increase in
cardiac remodeling in the form of LV dilatation ([LVEDD] 6.40.3mm vs 4.070.1mm, P
<0.0005) and eccentric LV hypertrophy ([LV mass] 187.113.5mg vs 107.66.9, P<0.0005), a
significant decrease in systolic function as evidenced by a significantly reduced LVEF
(21.91.9% vs 57.72.0%, P<0.0005), a significant loss in contractile reserve/ß-adrenergic
response([%change in LVEF] 8.77.2% vs 28.14.3%, P<0.05), and a significant decrease in
diastolic function in the form of increasing filling pressures ([LVEDP] 10.01.6mmHg vs
2.80.5mmHg, P<0.005)
Whereas data from our experimental mice groups treated with a 3.75 gr/kg or 7.50 gr/kg
OLT1177 diet (when compared to the control group) suggests that OLT1177 treatment led to
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restoration of contractile reserve (percent increase in LVEF after isoproterenol challenge (33 
11% or 40  6% vs +9  7 % in standard diet; P<0.05 and P<0.005 respectively). Treatment with
OLT 3.75 gr/kg or 7.5 gr/kg also led to preservation of diastolic function (left ventricular enddiastolic pressure 3.2  0.5 mmHg, or 4.5  0.5 mmHg vs 10.0  1.6 mmHg in standard diet;
P<0.005 and P<0.009). The data from our experimental OLT-treated mice groups show that
these effects were independent of the effects of ventricular remodeling, systolic function, and
contractility (+dP/dt, -dP/dt) after a nonreperfused AMI.
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CHAPTER 4: Discussion
How inflammation, dependent on the NLRP3 inflammasome, contributes to AMI, cardiac
remodeling, and HF progression, is a continuous and complex topic of research. Especially since
inflammation has been shown to be both beneficial and detrimental in processes following
myocardial injury. To further elucidate the efficacy of a novel targeted anti-inflammatory
strategy, this present study was designed to investigate both the role of the NLRP3
inflammasome after a nonreperfused AMI, and the effects that inhibiting NLRP3 could have on
blunting aberrant NLRP3 pro-inflammatory signaling following a severe AMI, thereby
potentially limiting the pathophysiological processes that occur in ischemic heart failure.
The results of this current study so far have shown that NLRP3 inhibition in OLT-treated
mice significantly preserved contractile reserve/ß-adrenergic response, as well as prevented left
ventricular diastolic dysfunction in a large nonreperfused anterior AMI, while having no effect
on limiting cardiac enlargement (dilatation) and left ventricular systolic dysfunction (reduced
LVEF). The majority of these results are in line with numerous past studies that have targeted
different levels of the NLRP3 molecular pathway, whether targeting downstream products such
as IL-1ß (Abbate et al., 2008), and caspase-1 (Frantz et al., 2003), or the more upstream targets
such as P2X7 receptor (Mezzaroma et al., 2011), MyD88 (B. Van Tassell et al., 2011), and the
NLRP3 inflammasome (Mezzaroma et al., 2011; Toldo et al., 2019).
As mentioned previously, the findings from a murine ischemia-reperfusion injury model
study by Toldo et al. in 2019 confirmed the potential clinical translational value of utilizing
OLT1177 as a cardioprotective strategy following myocardial injury. The findings from this
ischemia-reperfusion injury model study showed OLT177 having a reducing effect on cardiac
damage, as evidenced by limiting infarct size, LV systolic dysfunction, LV diameters, and
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caspase-1 activity. This previous study was also key in determining that intraperitoneal injection
of OLT1177 reaches maximal efficacy when given within one hour after reperfusion. In light of
these results, our study utilized OLT1177 in a long-term and more severe ischemic injury model.
We would expect NLRP3 inflammasome activation, oligomerization, and release of proinflammatory cytokines/signaling to have already been initiated and propagated by the time
OLT1177 diet was administered in our subjects. Thus, focusing on the efficacy of targeting the
upstream NLRP3 inflammasome by way of OLT1177 NLRP3 inhibition 1 week after myocardial
injury.
One particular study with a similar experimental design and results was conducted in
2014 by Toldo et al. In this study a nonreperfused AMI murine model was also used, along with
a mouse monoclonal antibody raised against mouse IL-1ß (10mg/kg) which was injected (i.p.)
one week after surgery for 9 weeks/once a week. The main findings from utilizing an IL-1ß
blockade strategy showed analogous results in regard to the significant preservation of diastolic
function and restoration of contractile reserve, while having no significant effect on cardiac
enlargement (Toldo et al., 2019). Where our results differ are on the positive effects that IL-1ß
blockade had on preserving systolic function. Possible reasons for this divergence can be
attributed to the differences in dosages, bioavailability, and efficacy of each experimental drug.
Another possible explanation can be due to differences in targets, with OLT1177 targeting the
more upstream NLRP3 inflammasome, whereas the IL-1ß antibody was directed against the
more downstream pro-inflammatory IL-1ß cytokine. On that account, it would seem plausible to
suggest that 1 week after a nonreperfused AMI, NLRP3 activation, oligomerization, and release
of cytokines such as IL-1ß may have already led to an enhanced post-infarction inflammatory
response characterized by chronic IL-1ß activity. Hence, the IL-1ß antibody could possibly be
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more effective at limiting systolic dysfunction due to targeting chronic IL-1ß activity, which in
previous studies has been shown to promote adverse cardiac remodeling and systolic dysfunction
(Bujak et al., 2008; Ørn et al., 2012). Nevertheless, without a side-by-side comparison analyzing
caspase-1 activity and cytokine levels, it would be difficult to fully ascertain the effectiveness of
each drug on systolic function.
Another study that used a nonreperfused AMI murine model was conducted by Marchetti
et al. in 2015 (Marchetti et al., 2015). Although this study had a shorter duration, their results
after injecting an NLRP3 inhibitor, a small molecule referred to as 16673-34-0 (100mg/kg) once
a day for 7 days following AMI surgery, show that the NLRP3 inhibitor, initiated after
myocardial ischemia, limited both cardiac enlargement and LV systolic dysfunction. Where our
study design and results differ from this study are on the positive effects that 16673-34-0 has on
limiting cardiac enlargement and preserving LV systolic function. A possible explanation for this
difference can be attributed to the timing of administration, in which 16673-34-0 was applied the
same day of the AMI, whereas in our study OLT1177 being applied 1 week after the AMI.
Another likely reason can be attributed to the duration of the study. When comparing a 10-week
nonreperfused AMI to a 1-week nonreperfused AMI it would be reasonable to expect to see a
more a severe form of adverse cardiac remodeling, with higher levels of caspase-1 activity
(mRNA synthesis) which according to a previous study by Mezzaroma et al. increases
severalfold in the heart 3-7 days after an AMI (Mezzaroma et al., 2011) and higher levels of IL1ß which has been shown to amplify the inflammatory response leading to higher degrees of
apoptosis, LV systolic dysfunction and severe cardiomyopathy in the mouse (Mezzaroma et al.,
2011) (B. W. Van Tassell, Seropian, et al., 2013).
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This present study had several potential drawbacks and limitations. Some of the more
common limitations seen in preclinical studies revolve around the use of mice, such as using
only one breed, using only relatively young healthy male mice, and having a small number of
subjects. For future studies, performing experiments on mice with other co-morbidities such as
diabetes mellitus, obesity, advanced age, or hypertension to simulate the present population most
at risk of developing cardiovascular diseases could be a way to limit these drawbacks. Another
limitation of this study is the subjective variability in transthoracic echocardiogram
measurements of LV dimensions and function.
Some of the more unique limitations that occur in our study are related to the method of
oral drug administration. As referenced earlier, our study’s experimental drug was admixed into
our subjects’ diet. With this form of administration potential drawbacks can occur. For example,
we noticed that both experimental mice groups during the first two-three weeks consumed a
lower amount of food containing OLT1177, which could be a potentially confounding feature of
the experiment. One way to address this limitation for future studies would be to implement
more precise and accurate drug administration methods, such as oral gavage or intraperitoneal
injections, as well as measuring test subjects’ blood/plasma regularly to ensure that the
appropriate therapeutic range of the experimental drug is being met throughout the study.
Another limitation of this study was not measuring inflammatory cytokine levels as done
in previous studies. Although this is a notable limitation, based on our results when compared to
findings from previous studies (Marchetti, Swartzwelter, Gamboni, et al., 2018b) (Toldo et al.,
2019) we infer that OLT1177 admixed into the experimental groups’ diet was effective at
inhibiting the NLRP3 inflammasome’s activity. Furthermore, our results give us reason to
believe that the inhibition of NLRP3 activation and oligomerization would follow and lead to
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reduced caspase-1 activity, less IL-1ß and IL-18 released, less pyroptotic cell death, and overall a
decrease in sterile inflammatory response. To address this limitation for future studies, mRNA
analysis of caspase-1 activity or cytokine levels (IL-1ß or IL-18), whether by Western blot
densiometric analysis or ELISA assay, would prove useful in helping to quantify the effects of
OLT1177 on post-infarction inflammatory response.
Despite these limitations, the results presented in this study show that NLRP3 inhibition
with OLT1177 can restore contractility reserve/ß-adrenergic responsiveness and prevent left
ventricular diastolic dysfunction after a large non-reperfused anterior AMI in mice, thereby
reducing the risk of developing post-infarct heart failure.
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CHAPTER 5: Conclusion
There is currently an urgent need to develop safe and effective therapeutic strategies to
prevent or treat heart failure. This need is drastically intensified in patient populations that have a
large myocardial infarction, do not receive effective reperfusion therapies in the appropriate
therapeutic window of time, as well as in patients with other comorbidities that lessen the effects
of reperfusion therapies. Based on the results from this present study and previous ones, reducing
the aberrant NLRP3 inflammasome signaling and the resulting exuberant inflammatory response
that follows a myocardial injury is a promising strategy. Therefore, these patients who are most
at risk of developing post-AMI adverse cardiac remodeling and heart failure would potentially
benefit the most from an NLRP3 inhibitor such as OLT177.
Even so, there are currently no targeted anti-inflammatory strategies routinely used for
preventing the inflammatory and pathophysiological processes that occur after an acute
myocardial infarction and during heart failure. To address this void, studies in the last ten years,
such as the CANTOS trial (Ridker et al., 2017), VCU-ART (Abbate et al., 2010), VCU-ART2
(Abbate et al., 2013), and REDHART (B. W. Van Tassell et al., 2017) have provided evidence in
support of implementing the concept of utilizing IL-1 blockade to inhibit the NLRP3 mediated
inflammatory response, in order to improve the outcomes of patients with severely damaged
hearts. With continued efforts, and further elucidation of the mechanisms and inflammatory
signaling processes that occur after a myocardial injury, more clinical trials investigating
inflammation as a potential target for therapeutic interventions are on their way.
Regarding the future translational value of utilizing OLT1177, one recent study has
shown promising anti-inflammatory effects of utilizing OLT1177 and a good safety profile in
patients with gout. Additionally, a recently completed phase 1b clinical trial, investigated the
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effects of OLT1177 (100mg dapansutrile capsules) in patients with systolic heart failure.
Although the results have not yet been published, if this study was able to confirm a protective
effect brought about by inhibiting the NLRP3 inflammasome, it follows that continued clinical
trials on OLT1177 may be warranted and one day help in preventing and treating heart failure.
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